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41 ABSTRACT
During the cord blood banking process vast amounts of data are gathered on
obstetric and infant related factors, in addition to information from laboratory
analyses and the blood processing itself. Current information technology offers
the means to explore ways of transforming these data into valuable information
for further development of cord blood transplantation. The aims of this study
were to explore the association between cord blood nucleated cell and CD34+
cell content through the standardised banking process and to analyse associations
of infant and obstetric characteristics with human leukocyte antigens as well as
with cord blood cell concentrations, in order to clarify the factors affecting the
quality of cord blood transplants.
Cord blood collections from healthy term infants (N=1999) were processed,
analysed and frozen for use as haematopoietic stem cell transplants in the Finnish
Cord Blood Banking programme between January 1999 and September 2003.
Data on obstetric and infant characteristics, as well as from cord blood bank
laboratory analyses and processing were collected prospectively and entered in
a spreadsheet application specifically developed for this purpose. Descriptive
analysis, the Mann-Whitney U-test, binary decision tree, and simple and
multivariate linear regression were the statistical methods used to compare
groups and control possible confounding effects. A method of comparing extreme
low and high centiles was additionally used to test the hypothesis of internal
associations between infant characteristics and cord blood cellular contents.
The volume reduction process was shown to be predictable. Correlation
between whole cord blood CFU concentration and cord blood unit CD34+ cell
concentration was excellent, suggesting that the methods as applied can be
used for evaluating the haematopoietic potential of cord blood transplants. No
associations between nucleated or CD34+ cell concentrations and ABO, Rh or
Kell blood groups were observed. HLA DRB1*13 was shown to be over-
represented in infants with the highest birth weights, suggesting a possible role
for HLA molecules or some unknown factor linked to the HLA DRB1 region of
chromosome 6 in normal intrauterine growth and development. The positive
association with HLA DRB1*13 remained when the birth weight was corrected
for varying gestational age according to gender (relative birth weight). As DRB1*13
has been associated with protection from e.g. infectious diseases, the mechanism
could be via molecular host responses. The possible association between tissue
types and haematopoietic progenitor and stem cell concentration of normal infant
may not be observed in future cord blood bank material, as cord blood collections
are currently focused on to yield mainly transplants with high cell counts. Birth
weight was shown to be the single most important factor for predicting higher
nucleated and CD34+ cell concentrations, as well as collected volumes. Thus
cord blood from high birth weight infant predicts the highest total cell contents
in collection. Female infants had higher nucleated cell concentrations, although
this consisted mainly of higher neutrophil concentrations. Instead, male infants
were shown to have higher CD34+ cell and colony forming unit concentrations.
Particularly, cord blood from male infants was shown to have, in caesarean section
5deliveries, more abundant early series haematopoietic progenitors than cord
blood from female infants.
In conclusion, obstetric and infant related factors may affect the quality of
haematopoietic stem cell transplants. Progenitor and stem cells, measured as
CD34+ or colony-forming cells in our study, may have a more central role in
intrauterine growth and development than has been reported earlier, which also
suggests possible differences in the growth potential of other stem cell lineages.
High birth weight, especially high relative birth weight of term infant, and male
gender were shown to be associated with higher concentration of hematopoietic
progenitor and stem cells.
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93 ABBREVIATIONS
ALL acute lymphoblastic leukaemia
BFU-E burst forming unit – erythroid
BMDW Bone Marrow Donors Worldwide
CAFC cobblestone area-forming cell
CFC colony forming cell / colony, see CFU
CFU colony forming unit, equivalent to CFC
CFU- Bas, basophil; E, erythrocyte; Eos, eosinophil; G, granulocyte;
GEMM, granulocyte-erythrocyte-macrophage-megakarycyte
(equivalent to CFU-Mixed); GM, granulocyte-macrophage; M,
macrophage; Meg, megakarycyte;
CFU-TOT sum of CFU-GM, CFU-GEMM and BFU-E
CI confidence interval
c-kit c-kit ligand, mast/stem cell growth factor, steel factor
CRU competitive repopulating unit
DFS disease-free survival
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
EFS event-free survival
G-CSF granulocyte colony-stimulating factor
GM-CSF granulocyte-macropahge colony-stimulating factor
GMP good manufacturing practice
GVHD graft-versus-host disease
HBs-Ag hepatitis B surface antigen
HCV hepatitis C virus; anti-HCV, antibodies against HCV
HIV1/2 human immunodeficiency virus 1/2; anti-HIV1/2, antibodies
against HIV1/2
HLA human leukocyte antigen
HPP-CFC high proliferating potential CFC
HTLV-I/II human T-cell lymphotrophic virus I/II
LTC-IC long-term culture-initating cell
MHC major histocompatibility complex
NMDP National Marrow Donor Program
NOD/SCID non-obese diabetic / severe combined immunodeficiency
n.s. non-significant
OS overall survival
PBSC peripheral blood stem cell
SOP standard operational procedure
SRC NOD/SCID mouse repopulating cell
TRM transplant related mortality
WMDA World Marrow Donor Association
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4 INTRODUCTION
The potential of bone marrow derived cells to prevent radiation induced death
was recognised in the 1950s, first in animal experiments and later also in humans
(Jacobson LO et al., 1949, Lorenz E et al., 1951, Thomas ED et al., 1957, Thomas
ED, 1999). The first bone marrow transplantations were performed in the late
1960s (Gatti RA et al., 1968, Thomas ED, 1993), and by the following decade
haematopoietic reconstitution using bone marrow derived cells was an
established procedure (Thomas ED et al., 1975a, Thomas ED et al., 1975b). The
1990 Nobel Prize in Medicine was given to E. Donnall Thomas for developing
methods to control graft-versus-host disease using the cytotoxic drug
methotrexate, thus enabling allogeneic bone marrow transplantations (Thomas
ED, 1993).
Bone marrow transplantations began in Finland in the early 1970s (Volin L et
al., 1984). The first related allogeneic paediatric transplantation was performed
at the Children’s Hospital 1974 (Makipernaa A et al., 1995), and at Meilahti Hospital
on an adult patient in 1981 (Ruutu T, 2004, personal communication). In the
1990s the use of unrelated bone marrow donors began, in parallel with the
development of donor registries in several European countries (Cleaver SA, 1993,
Oudshoorn M et al., 1994).
Haematopoietic stem cells are also present in the blood of newborn children
and can be safely collected from the umbilical cord and placenta after birth
(Knudtzon S, 1974, Broxmeyer HE et al., 1989, Gluckman E, 2000, Broxmeyer
HE, 2004). As a third to a quarter of patients in need of haematopoietic stem cell
transplantation lack a suitable donor, additional sources of haematopoietic stem
cells have been sought (Gluckman E et al., 1989).
The haematopoietic progenitor cell content of cord blood is considered different
from adult haematopoietic progenitor cells. In the 1990s, cord blood became
widely accepted as a source of stem cells for allogeneic haematopoietic
reconstitution, and lately also for adult patients, although the available cord blood
cell dose is smaller than that which can be collected from adult donors. Until a
direct laboratory test for stem cells is developed, final validation of the suitability
of a cord blood transplant as source of potent stem cells can only be obtained
through clinical transplantation. For secure and prompt procurement of cord
blood units for transplantation, cord blood banks with frozen repositories of well-
characterised cord blood units have been established all over the world (Rubinstein
P et al., 1994, Armitage S et al., 1999b, Mugishima H et al., 2002, Rebulla P,
2002).
In this study the vast amount of data gathered in the cord blood banking
process was utilised to analyse both the cord blood units as well as various
relevant infant physiological phenomena in order to characterise and improve
the quality of cord blood stem cell transplants.
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5 REVIEW OF THE LITERATURE
5.1 Cord blood haematopoietic stem cells
Human and mice haematopoietic stem cells bear close resemblance, and
understanding of the human haematopoietic system is fundamentally based on
studies in mice (Manz MG et al., 2004, Orkin SH and Zon LI, 2002).
5.1.1 Haematopoiesis
Blood formation begins in embryonal mesoderm, from where primitive
extraembryonic haematopoiesis in yolk sac and definitive intraembryonic
haematopoiesis in aorta-gonad-mesonephros (AGM) region are derived (Godin I
et al., 1995, Orkin SH and Zon LI, 2002). Primitive erythroblasts and CD34+
haematopoietic cells are first detectable in the human yolk sac after 18.5 days of
development, and cells with both lymphoid and myeloid potential have been
detected in the AGM region between 24-34 days (Galloway JL and Zon LI, 2003).
The haematogenic endothelium found in the dorsal aorta is thought to originate
from the AGM region (Robin C et al., 2003). Association of haematopoiesis and
angiogenesis is close, suggesting a common precursor cell known as the
haemangioblast (Shalaby F et al., 1995, Choi K, 2002). Stem cells migrating via
the blood stream are belived to be responsible for the transition of haematopoiesis
from the human yolk sac or, more probably, from the AGM region, to liver
(Migliaccio G et al., 1986, Orkin SH and Zon LI, 2002). At the 7th week of gestation,
the liver is the main haematopoietic organ (Galloway JL and Zon LI, 2003). The
long-term contribution of primitive haematopoiesis is controversial and may be
species-dependent (Orkin SH and Zon LI, 2002). Definitive normoblastic
erythropoiesis accounts for more than 90% of the circulating erythrocytic cells
by 10th week of gestation (Brugnara C and Platt OS, 2003). During the third month
of gestation, haematopoiesis can also be detected in spleen, thymus and lymph
nodes. Haematopoiesis begins in bone marrow during the fourth to fifth months
of gestation. From the sixth month of gestation, bone marrow is the principal
site of haematopoiesis, although blood cell formation can be detected in liver
and spleen until the first postnatal week (Brugnara C and Platt OS, 2003).
Morphologically, haematopoietic stem cells are medium-sized mononuclear
cells with a high nuclear-cytoplasmic ratio, basophilic cytoplasm with no granules,
and prominent nucleoli; they cannot, however, be classified based on the
appearance under a light microscope (Clark SC et al., 2003).
Lineage plasticity of the haematopoietic stem cells. In classical models of
haematopoiesis (Figure 1), pluripotent stem cells self-replicate while occasionally
differentiating into a stage of more differentiated progeny and thus losing their
multipotency (Till JE et al., 1964, Clark SC et al., 2003). Recently, non-classical
models of haematopoiesis – e.g. unified stem model (Quesenberry PJ et al.,
2002) and phase space model (Kirkland MA, 2004) – have been introduced. These
models propose, instead of the irreversible hierarchical differentiation of
haematopoietic stem cells that these cells may, under appropriate circumstances,
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re-differentiate exceeding even the embryonic-derived lineage specific boundaries
(Martin-Rendon E and Watt SM, 2003). Mechanisms involved in proposed lineage
plasticity of stem cells include multiple factors, e.g. cytokine and growth factor
networks in the microenvironment, niches, of the stem cells (Spradling A et al.,
2001), as well as chromatin modulation (Quesenberry PJ et al., 2002) and changes
in gene expression (Cai J et al., 2004) during the cell cycle. However, until now,
several studies on stem cell plasticity and transdifferentiation have reported
controversial findings (Wagers AJ and Weissman IL, 2004).
Multipotent mesenchymal stem cells capable of differentiating into cell types
of all three germ layers have also been detected in cord blood (Lee OK et al.,
2004). Further, possibilities of differentiating cord blood mesenchymal cells into,
e.g., neural or muscle cells are being studied (Bicknese AR et al., 2002, Gang EJ
et al., 2004).
Figure 1 A simplified representation of the hierarchical differentiation of
haematopoietic stem cells. Laboratory assays have been developed to identify cells
at various levels of differentiation; for abbreviations, please refer to chapter 3.
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Foetal haematopoietic stem cells
Haematopoietic stem cells have been detected in foetal tissues in early gestation.
Hann and collaborators studied haematopoietic progenitor cells (CFU-GEMM,
CFU-GM and BFU-E) in clonogenic cultures from human foetal samples between
12 and 23 weeks of gestation. CFU-GEMM colonies were observed in liver in all
fetuses, whereas they were first detected in bone marrow at 15 weeks and in
spleen at 18 weeks of gestation, foetal thymus showing no haematopoietic
activity. In blood samples of four foetuses between 13 and 21 weeks of gestation
high levels of 9-50 CFU-GEMM, 80.5-400 CFU-GM and 119-364 BFU-E colonies
per 105 plated cells were observed (Hann IM et al., 1983). Linch and collaborators
studied foetal blood samples between 12.5 and 19 weeks of gestation. The
increase in foetal CFU-GM growth was greater when placental conditioned
medium was added to provide exogenous colony-stimulating factors, compared
to the growth of CFU-GM obtained from adult bone marrow; in addition, foetal
BFU-E were more sensitive to erythropoietin than BFU-E obtained from adult
peripheral blood (Linch DC et al., 1982). In samples of foetal blood, Zauli and
collaborators observed that the sensitivity of BFU-E at 18-22 weeks of gestation
to suboptimal concentrations of erythropoietin was approximately 10-15-fold
higher than the sensitivity of adult BFU-E (Zauli G et al., 1994). Haematopoietic
progenitor cell concentration, measured as CFC, is approximately 0.134/µl during
weeks 10-11 of gestation reaching a peak value of 65/µl at 18 weeks and declining
thereafter to 10/µl at the time of birth (Mayani H et al., 2003). Thus, foetal
haematopoietic stem cell concentration appears to be high in mid-gestation and
to decline thereafter.
5.1.2 Methods to analyse haematopoietic stem cells
Full blood counts
Nucleated cell content has been used to predict haematopoietic stem cell
potential, both in bone marrow and cord blood transplantations (Lim F et al.,
1999, Rocha V et al., 2002). Nucleated cells of blood samples are routinely
enumerated, using electrical impedance method, by automated haematology
analysers (Dacie JV and Lewis SM, 1985), which provide the concentration of
nucleated cells, red cells and platelets, as well as the differential relative count
of nucleated cells from which the mononuclear cell fraction can be estimated.
Depending on the equipment, an enumeration of nucleated red blood cells may
also be available (Stevens CE et al., 2002, Wang FS et al., 2003). Using a
combination of electric impedance and electric capacitance detection, modern
haematology analysers can provide a more direct estimate of the immature cell
content, representing possibly haematopoietic stem cells (Takekawa K et al.,
1998, Creer MH, 2003 [abstract], Wang FS et al., 2004). As the measurement
principles of haematology analysers vary greatly, nucleated cell counts from
different laboratories may not always be comparable (Eichler H et al., 2004).
Flow cytometric analyses
Numerous immunophenotypes to identify haematopoietic stem cells have been
studied. Hector and Mayani in their review conclude from several studies that
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immunophenotype CD34+ CD38- CD45RAlow CD71low Thy-1+ c-kitlow Rhlow
represents a primitive cord blood haematopoietic progenitor cell (Mayani H and
Lansdorp PM, 1998). Detecting high alhehyde dehydrogenase activity as a sign
of conserved stem cell function has also been used (Hess DA et al., 2004). Despite
the intensive research on other markers, however, CD34 remains the widest
used surface marker of haematopoietic progenitor and stem cells in clinical
practice.
CD34. CD34 is a highly O-glycosylated transmembrane protein with a molecular
weight of 115 kDa (Satterthwaite AB et al., 1992). The gene is located at band
1q32 in the long arm of chromosome 1. The CD34 gene extends 26kb and eight
exons code the protein. The CD34 protein consists of five domains: an N-terminal
part, a region rich in glycosylation sites, a membrane-proximal domain, a
transmembrane region and a cytoplasmic tail (Simmons DL et al., 1992). The
cytoplasmic tail of human CD34 has the highest degree of homology, 92%, with
that of the murine CD34, suggesting an important functional role (Sutherland
DR and Keating A, 1992, Krause DS et al., 1996). This region contains known or
potential protein kinase target sites (Fackler MJ et al., 1992).
CD34 was identified twenty years ago using antibodies against a human
myeloblastic leukemic cell line (Civin CI et al., 1984, Tindle RW et al., 1985, Katz
FE et al., 1985). Different antibodies detected distinct, non-overlapping epitopes
(Watt SM et al., 1987, Lanza F et al., 2001). CD34 is expressed on developmentally
early lymphohaematopoietic progenitor and stem cells, small-vessel endothelial
cells and embryonic fibroblasts (Krause DS et al., 1996) and also in some leukaemic
cell lines (Bahia Kerbauy DM et al., 2003), but not generally in solid tumours
(Krause DS et al., 1996).
CD34+ cells comprise approximately 1.5% of bone marrow mononuclear cells.
The surface expression of CD34 decreases to undetectable levels by the stage
that maturing haematopoietic cells lose their capacity to form colonies in cultures
(Strauss LC et al., 1986). The CD34+ cell population includes virtually all
haematopoietic progenitors analysed using colony-forming assays (Sutherland
DR and Keating A, 1992). Purified bone marrow CD34+ cells have also been
demonstrated to be able to reconstitute all haematopoietic lineages after
myeloablative therapy (Berenson RJ et al., 1991).
Roles of CD34 in leukocyte adhesion on vascular endothelium (Fina L et al.,
1990, Baumheter S et al., 1993, Baumhueter S et al., 1994), in progenitor and
stem cell localisation and adhesion in bone marrow (Healy L et al., 1995), and in
maintenance of the haematopoietic stem/progenitor phenotype (Fackler MJ et
al., 1995) have been suggested. However, despite vast amounts of scientific
work, the biological function of CD34 has remained elusive (Lanza F et al., 2001).
Cord blood CD34+ cells. Sensitive flow-cytometric methods to detect CD34+
cells also from cord blood have been developed . In these methods, DNA dye
positive cells are further classified to separate CD45negative-week CD34+ cells from
mature CD45+ CD34neg leukocytes. CD34+ cells can be detected either using a
single or dual platform protocol. Dual platform refers to a protocol, where the
CD34+ cell concentration in the sample is counted using the flow-cytometrically
obtained relative CD34+ cell content within nucleated cell or white blood cell
count, which in turn is obtained from a haematology cell analyser. In a single
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platform protocol a known number of highly fluorescent beads are added to the
known sample volume and the bead count is used to calculate the analysed
sample volume and then its CD34+ cell concentration (Gratama JW et al., 1999).
Mean relative contents of CD34+ cells in cord blood of 0.25-0.42% have been
reported (Surbek DV et al., 2000c, Solves P et al., 2001).
As the result of colony-forming assays is obtained only after approximately
two weeks, and as the CD34+ cell content of cord blood correlates well with the
colony-forming cell content (Law P et al., 1993, Encabo A et al., 2003), CD34+
cells are now routinely analysed in cord blood banks as a surrogate marker of
the haematopoietic progenitor and stem cell content of cord blood transplants.
Although haematopoietic progenitors have also been reported among CD34
negative cells (Nakamura Y et al., 1999), the improtance of CD34 in current practice
cannot be overemphasised.
A median number of transplanted CD34+ progenitor cells of 1.2-1.5 *105 per
kilogram of patient weight has been repored (Thomson BG et al., 2000, Laughlin
MJ et al., 2001). Wagner and collaborators reported better myeloid engraftment,
lower treatment-related mortality and higher survival in patients who had received
more than 1.7 *105 cord blood CD34+ cells per kilogram (Wagner JE et al., 2002).
However, as the interlaboratory replicability of CD34+ cell analyses is still not
standardised (Barnett D et al., 1998), the CD34+ cell content alone cannot be
used to select a cord blood transplant for a patient.
Neonatal CD34+ cells. Neonatal CD34+ cell concentration has been shown to
decline from 19.3 /µl to one third between two and 48 hours of life, the rate of
decline being greatest during the first four hours (Li K et al., 1999). Reason for
this phenomenon is not known. Delivery stress mediated mechanisms may
contribute to high cord blood CD34+ cell counts at birth. However, as only minor
differences between the cord blood CD34+ cell content in vaginal and caesarean
section deliveries have been reported (Sparrow RL et al., 2002, Solves P et al.,
2003c), regulation during fetal maturation probably plays a more important role.
CD133. CD133, a glycoprotein with a molecular weight of 120kDa, is selectively
expressed only on CD34+ human haematopoietic progenitor cells and not on
other blood cells, umbilical vein endothelial cells, fibroblast cells or the myeloid
leukaemia cell line used to originally identify CD34 (Yin AH et al., 1997). Recently,
cord blood CD133+ cells have been isolated on a clinical scale and shown to
have repopulating activity in NOD/SCID mouse, and mesenchymal potential in
vitro (Bonanno G et al., 2004). Accumulating clinical transplantation data will
hopefully clarify the relevance of CD133 as a useful potential transplantation
antigen.
Cell cultures
Colony-forming cells (CFC; colony-forming unit, CFU). Haematopoietic progenitor
cells have been analysed using colony-forming cell cultures (Ma DD et al., 1987).
In these cultures nucleated cells plated on a semi-solid medium in the presence
of cytokines are incubated in a humidified environment at +37°C with 5% CO2
for 14 days (Broxmeyer HE et al., 1989), after which the BFU-E, CFU-GM and
CFU-GEMM colonies are enumerated under a light microscope (Eaves C and
Lambie K, 1995). Lowered O2 tension has also been studied in order to boost the
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incidence of detectable progenitor cells (Smith S and Broxmeyer HE, 1986,
Broxmeyer HE et al., 1989, Ivanovic Z et al., 2000).
Difficulties in standardising colony forming culture techniques has lead to
problems in interpreting uneven results between laboratories (Lumley MA et al.,
1999, Lamana M et al., 1999). However, these methods may be used in internal
comparisons until better standardisation of colony forming cell assays has been
achieved.
Cord blood CFC. The existence of haematopoietic progenitor colonies in human
cord blood was demonstrated in 1974 by Søren Knudtzon, who reported 122
granulocytic colonies per 2*105 cord blood nucleated cells plated compared with
3 colonies per 2*105 adult peripheral blood nucleated cells plated (Knudtzon S,
1974) (Figure 2).
Concentrations of haematopoietic progenitor cells in cord blood and bone
marrow have been in the focus of several studies, and primitive CFU-GEMM and
BFU-E colonies have been reported to be more abundant in cultures of cord
blood (Hows JM et al., 1992, Kasai M and Masauzi N, 1998, Mayani H et al.,
1998). Haneline and collaborators studied cord blood samples collected after
the birth of normal term and preterm infants at 23-41 weeks of gestation. They
reported concentrations of 3.9/µl of HPP-CFC (see Section Long-term cultures),
11/µl of CFU-GEMM/BFU-E and 10.6/µl of CFU-GM at 23-31 weeks of gestation,
compared with 1.1/µl, 3.2/µl and 2.9/µl of respective CFC at 32-41 weeks (Haneline
LS et al., 1996). However, Migliaccio and collaborators reported a two-fold higher
CFC concentration of 41/µl in term cord blood compared with 18/µl at 17-32
weeks of gestation. In their study, foetal blood samples were obtained via umbilical
vein puncture, whereas cord blood samples were obtained after birth (Migliaccio
G et al., 1996). Sample techniques and culture conditions probably affect the
observed CFC levels. Ogawa and collaborators showed that cord blood contains
blast cell colonies with high replating frequency, thus indicating the presence in
cord blood of primitive haematopoietic progenitor cells (Nakahata T and Ogawa
M, 1982, Leary AG and Ogawa M, 1987). Broxmeyer and collaborators analysed
the properties of cord blood in a banking setting and reported comparable
frequencies of haematopoietic progenitor cells with those reported for successfull
engraftment with bone marrow cells (Broxmeyer HE et al., 1989). The
concentration of colony-forming cells in cord blood samples obtained from full-
term deliveries is approximately 7-8/µl for BFU-E, 13-24/µl for CFU-GM and 1-11/
µl for CFU-GEMM (Abboud M et al., 1992, Traycoff CM et al., 1994).
Cord blood haematopoietic progenitor cells also tend to grow in cultures with
limited external cytokine addition when compared with adult cells (Valtieri M et
al., 1989). When colony forming cultures of samples from fetuses (17-32 weeks
of gestation), term cord blood and adults were compared, the number of cytokines
required to observe maximal colony formation increased along with the
ontogenetic stage of the cells (Migliaccio G et al., 1996). Carow and collaborators
showed that replated cord blood CFU-GEMM colonies gave rise to CFU-GEMM,
BFU-E and CFU-GM colonies in secondary cultures, whereas bone marrow CFU-
GEMM produced mainly CFU-GM colonies (Carow CE et al., 1991). In the study
of Migliaccio and collaborators, even tertiary replatings were possible from foetal
CFU-GM and CFU-Mixed, as well as from cord blood CFU-Mixed colonies, but
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not from cultured adult samples (Migliaccio G et al., 1996). These findings suggest
that cord blood haematopoietic progenitor cells have an elevated proliferation/
expansion potential compared with cells from adult sources.
Published data concerning the assessment of cord blood colony forming units
in the transplant setting are scarce. Migliaccio and collaborators reported stronger
association of myeloid engraftment, platelet engraftment and post-transplantation
events with a transplanted cord blood CFC dose than with a nucleated cell dose
in a multivariate model (Migliaccio AR et al., 2000). The association between
CFU-GM dose and time to engraftment has been demonstrated using other stem
cell sources, e.g. autologous or allogeneic bone marrow, or peripheral stem cells
(Spitzer G et al., 1980, Douay L et al., 1986, Ma DD et al., 1987, Schwartzberg L
et al., 1993). Stronger correlation between cord blood CD34+ cell and colony
forming cell concentration than between cord blood nucleated cell and colony
forming cell concentration has been reported (Lim F et al., 1999), supporting the
hypothesis that colony forming cells are a true predictor of clinical success.
Neonatal blood CFC. Compared with cord blood, neonatal blood contains
haematopoietic progenitor cells - measured as CAFC and LTC-IC (see Section
Long-term cultures) - at equivalent levels shortly after birth (Zhang XB et al.,
2002). High levels of colony forming cells have been detected in cord (3050 CFC/
ml) and neonatal blood during the first month of life (330 CFC/ml), the levels
declining from the second month onwards to the level detected in adults (second
month 88 CFC/ml vs. adults 60 CFC/ml) (Gabutti V et al., 1975). Also, Geissler
and collaborators reported 26-fold higher levels for CFU-GM, seven-fold for BFU-
E and five-fold for CFU-Mixed colonies in infants aged between one day and 10
weeks, compared with adult values (Geissler K et al., 1986). Therefore, as neonatal
blood contains haematopoietic progenitor cells measured both as colony forming
and CD34+ cells, it has been studied in cord blood transplantation (Li K et al.,
1998).
Long-term cultures. Colony-forming cells with high proliferative potential (HPP-
CFC) have been described in human bone marrow samples after an extended
culture of 28 days in 10% CO2 / 7% O2 conditions (McNiece IK et al., 1989). Cells
with high proliferative potential have also been found in cord blood after 21 days
of culture in 5% CO2 / 5% O2 in approximately eight-fold higher frequency than in
bone marrow, and are believed to represent more primitive progenitor cells than
CFU-GEMM (Lu L et al., 1993). A long-term culture-initiating cell (LTC-IC), an
even more primitive cell type, has been characterised using long-term cultures
of five weeks to prevent the growth of differentiated clonogenic progenitor cells
(Sutherland HJ et al., 1989, Sutherland HJ et al., 1990). Pettengell and collaborators
reported equivalent proportions of cord blood and bone marrow LTC-IC (1/35000
and 1/34000, respectively) after an eight-week culture of mononuclear cells, the
proportion of leukapheresis LTC-IC being 1/13000 (Pettengell R et al., 1994).
Primitive haematopoietic clones can also be analysed in phase-contrast
microscopy as they form phase-dark cobblestone-like areas (Breems DA et al.,
1994). Cord blood derived CD34+ cells have been reported to contain six-fold
higher numbers of these cobbelstone area forming cells (CAFC) than
corresponding cells from bone marrow (Theilgaard-Monch K et al., 1999). Thus,
cord blood appears to contain more primitive haematopoietic progenitor and
stem cells compared with adult sources.
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Viability
The permeability of the cell membrane of dying cells increases. Non-viable cells
can thus be estimated by using reagents staining the damaged cells (Kaltenbach
JP et al., 1958, Freshney RI, 2000); e.g. 7-amino-actinomycin (7-AAD) and Trypan-
Blue have been used in assessment of cell viability of cord blood samples (Xiao
M and Dooley DC, 2003). Measurements of 7-AAD negative CD34+ cells by flow
cytometry are expected to yield an accurate gauge of viable CD34+ cells in cord
blood.
In vivo assays
An estimation of even more primitive haematopoietic stem cell content has been
developed experimentally using severe combined immunodeficiency (SCID) mice
in an in vivo assay (McCune JM et al., 1988, Vormoor J et al., 1994). In SCID mice
repopulating cell (SRC) or competitive repopulating unit (CRU) assays, the
haematopoietic reconstituting capacity of stem cells is evaluated by transplanting
the cells using limiting dilution in SCID mice strain (Conneally E et al., 1997). The
frequency of SRC in cord blood has been found to be 1/9.3*105 cells compared
with 1/3.0*106 in bone marrow and 1/6.0*106 in mobilised peripheral blood (Wang
JC et al., 1997).
Figure 2 The first report on colony forming colonies in human cord blood. From:
Knudtzon S. In vitro growth of granulocytic colonies from circulating cells in human
cord blood. Blood 1974;43(3):357-61. Copyright of American Society of
Hematology, used with permission.
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5.2 Major histocompatibility complex (MHC)
The existence of a histocompatibility locus controlling the rejection of foreign
tissues was first demonstrated in mice (Snell GD and Higgins GF, 1951, Amos
DB et al., 1955). Human major histocompatibility complex (MHC) was recognised
a few years later in studies of leukocyte antibodies of multiple transfused patients
(Dausset J, 1954). Leukocyte antibodies were also detected in sera of multiparous
women (Van Rood JJ et al., 1958). Epitopes of these antibodies, HLA antigens or
HLA molecules, participate in the immune response and are encoded by genes
in MHC area of the short arm of chromosome 6 (Mickelson E and Petersdorf EW,
2004).
HLA molecules are devided in two classes, I and II, which differ somewhat in
their structure as well as function (Klein J and Sato A, 2000). HLA molecules of
both classes feature in their structure a peptide-binding groove and a
transmembrane region binding the molecule to cell membrane. Foreign antigens
are prosessed intracellularly and bound to the peptide-binding groove of an HLA
molecule. The HLA molecule-peptide complex is then transported to cell surface,
where it is presented to T-cells for eliciting an immune response. Class I HLA
molecules bind and subsequently present peptides originating from intracellularly
produced foreign proteins after e.g. viral infection of a cell. Thus, the expression
of class I molecules by virtually all somatic cells is understandable. By contrast,
class II HLA molecules bind and present peptides derived from extracellular
proteins after endocytosis and intracellular processing and are expressed
predominantly in the cells of the immune system. T-cell recognition of the HLA
molecule-peptide complexes is the basis of auto- and allorecognition.
There are several gene loci in the HLA system, of which class I A and B and
class II DRB are considered the most important in tranplantation immunology
(Klein J and Sato A, 2000). The HLA system is extensively polymorphic (Marsh
SG et al., 2002), the number of different alleles identified in loci A, B and DRB
being more than 1300 (Turner D, 2004).
5.2.1 Disease associations
HLA alleles have been associated with protection from or susceptibility to
numerous diseases, e.g. autoimmune diseases such as diabetes and coeliac
disease, and also malignant diseases (Tiwari JL and Terasaki PI, 1985, Posthuma
EF et al., 1999, Lechler R and Warrens A, 2000).
HLA DRB1*13, in particular, has been associated with protection from
infectious diseases, such as malaria (Hill AV et al., 1991), human papillomavirus-
associated cervical carcinoma (Apple RJ et al., 1994), and chronic hepatitis B
virus infection (Thursz MR et al., 1995).
5.2.2 HLA match
A close match between donor and recipient HLA antigens has been considered
of fundamental importance for the success of haematopoietic stem cell
transplantation (Thomas ED, 1999, Morishima Y et al., 2002). Based originally on
HLA types obtained using serological methods, HLA matching is currently
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perfomed from DNA samples on an appropriately defined level using molecular
methods (Mickelson E and Petersdorf EW, 2004). The donor and recipient have
been at least matched for the A and B antigens as well as for DRB1 allele groups
(6/6 match). Matching for other alleles/antigens, such as HLA C and so-called
minor histocompatibility antigens, probably also influences the transplantation
results (Elia L et al., 1999, Kogler G et al., 2002, Flomenberg N et al., 2004).
In cord blood transplantations, compared with bone marrow transplantations,
less stringent HLA matching between patient and the donor has yielded favourable
outcomes (Tables 1-3). Even 4/6 matches are accepted, provided the total
transplanted cord blood cell dose is adequate (See Chapter 5.3.1 for Dose). For
example, Rubinstein and collaborators reported only 7% of 6/6 matches in their
study on 562 unrelated cord blood transplantations (Rubinstein P et al., 1998).
Recently, in adult double cord blood transplantation, favourable outcomes with
relatively low graft-versus-host disease have been reported. In these
transplantations, an HLA match of 4/6 between the patient and both grafts as
well as between the two grafts has been accepted (Barker JN et al., 2005).
However, although HLA match requirements in cord blood transplantation might
be more permissive than in transplantation of haematopoietic stem cells from
adult donors, better HLA matching has been associated with better results also
in cord blood transplantation (Rubinstein P and Stevens CE, 2000).
Haematopoietic stem cell transplants are primarily selected also according to
ABO blood groups. As cord blood does not contain isoagglutinins, minor blood
group discrepancy is not an issue in cord blood transplantation if the donor
mother is not ABO immunised. Associations between blood groups and
haematopoietic stem cell content of the graft have not been reported.
5.3 Allogeneic unrelated haematopoietic stem cell transplantation
Although excellent results in the treatment of malignant haematopoietic disorders
with intensive chemo-radiotherapy regimens are being achived (Saarinen-Pihkala
UM et al., 2004), allogeneic haematopoietic stem cell transplantation is integrated
in the therapeutic plan of many malignancies as well as severe non-malignant
haematopoietic disorders (Gratwohl A, 2004). In addition to the characteristics
of the haematopoietic transplant itself - e.g. cell content, ABO- and HLA
compatibility - the results of haematopoietic stem cell transplantation are affected
by diagnosis, treatment, phase of the disease, timing of transplantation, and
conditioning of the patient for the transplantation, as well as by the experience
of the transplantation team.
Data on the results of haematopoietic stem cell transplantations have been
collected and analysed in international efforts starting in the 1970s (Goldman
JM and Horowitz MM, 2002, Gratwohl A, 2004). The yearly worldwide number
of autologous haematopoietic stem cell transplantations has not increased since
the 1990s, while the number of allogeneic haematopoietic stem cell
tranplantations has increased steadily. In 2002, 20 207 haematopoietic stem cell
transplantations were performed in Europe, of which 6 915 were allogeneic, i.e.
transplanted stem cells were collected from another individual, and 13 292
autologous, i.e. transplanted stem cells were collected previously from the same
individual (Gratwohl A, 2004).
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In 2003, 1 011 bone marrow and 1 188 peripheral blood stem cell transplants,
as well as 963 unrelated cord blood units from unrelated donors were provided
for transplantation, indicating a high use of cord blood for transplantation (Annual
report 2003 of the World Marrow Donor Association) (Marry E and Oudshoorn
M, 2004, Oudshoorn M and Foeken-van Goozen L, 2004). About one-third of the
almost 3000 patients receiving cord blood transplantation to date through Netcord
network (see 5.4.9 Cord blood banks and networks) have been adults (Netcord
inventory and use, www.office.de.netcord.org, accessed July 2004).
5.3.1 Haematopoietic stem cell transplantation - concepts
Haematopoietic stem cell collection
Bone marrow. Haematopoietic stem cells can be harvested by bone marrow
aspirations under general or spinal anesthesia (Thomas ED and Storb R, 1970,
Buckner CD et al., 1984). An average of 9.5 ml of bone marrow per kilogram
donor weight, containing 2.2 *108 nucleated cells, was harvested from an adult
donor (Buckner CD et al., 1984). Thus, a bone marrow transplant collected from
a donor weighing 70 kg would contain 154 *108 nucleated cells. The risk of
serious, life-threatening complications to bone marrow donors has been reported
to be 0.3% (Bortin MM and Buckner CD, 1983, Stroncek DF et al., 1993).
Peripheral blood stem cells. Peripheral blood contains increasing numbers of
haematopoietic stem cells during the recovery phase of cytotoxic treatment or
after growth factor stimulation (Goldman J, 1995). Collection after G-CSF or GM-
CSF mobilisation of marrow haematopoietic stem cells using an apheresis device
has been increasingly used in allogeneic transplant settings (Russell N et al.,
1996, Champlin RE et al., 2000). Peripheral blood stem cells differ from those of
bone marrow, e.g. the CD34+ cell content of a peripheral blood stem cell graft
may be five-fold (Russell N et al., 1996). Two-to-3 *106 CD34+ cells per kilogram
of patient weight has been regarded as a minimum dose for allogeneic
transplantation (Russell N et al., 1996). The apheresis procedure is considered
as safe as marrow harvesting (Anderlini P et al., 2001, Favre G et al., 2003). Use
of peripheral blood from minor donors has also been studied (Lipton JM, 2003).
Conditioning
To diminish the leukaemic cell burden and to enable engraftment of transplanted
haematopoietic stem cells by suppressing the immunological defense of the
recipient, a conditioning treatment is given to patients prior to transplantation.
The treatment consists of cytotoxic regimens and irradiation, either alone or in
varying combinations depending on the diagnosis and the phase of the disease
(Bensinger WI and Spielberger R, 2004). Recently, non-myeloablative conditioning
regimens emphasising the immunologic effects of the transplant have also been
studied in cord blood transplantations (Rizzieri DA et al., 2001, Barker JN et al.,
2003, Alyea EP et al., 2004, Barker JN et al., 2004 [abstract]). The possibilities of
modifying conditioning regimens are numerous but may have remained
somewhat unexplored due to the many variables in clinical patient care.
22
Dose
As a quick and reliable characterisation of haematopoietic progenitor and stem
cells is not yet possible, the haematopoietic cell content of a transplant is generally
estimated according to its total nucleated cell count. A higher number of infused
adult nucleated cells per kilogram of body weight has been associated with
increased speed of engraftment as well as with improved survival of the patient
due to reduction in the incidence of graft rejection in related (Niederwieser D et
al., 1988) as well as in unrelated (Sierra J et al., 1997) bone marrow
transplantations.
In cord blood transplantations, higher transplanted nucleated cell dose has
been positively correlated with the speed and probability of myeloid and platelet
engraftment (Rubinstein P et al., 1998, Gluckman E et al., 2004). The nucleated
cell number is seldom a limiting factor in adult donor settings, as adequate cell
numbers can usually be collected from the donor (Buckner CD et al., 1984).
Generally, 2-3*108 bone marrow nucleated cells have been given per kilogram of
patient body weight (Davies SM et al., 2000, Rocha V et al., 2002). Notably, in
cord blood transplantation, one log lower dose of 2 *107 cord blood nucleated
cells per kilogram is used (Gluckman E, 2001).
Myeloid and platelet engraftment
A marker of initial success of haematopoietic stem cell transplantation is myeloid
and platelet engraftment. Engraftment refers to the time when haematopoietic
stem cells infused into the circulation during transplantation begin producing
the blood cells. Myeloid engraftment is normally defined as the first of three
consecutive days with an absolute neutrophil count >0.5*109/l and platelet
engraftment as the first of seven consecutive days with a platelet count
>50*109/l without platelet transfusions (Bryant E and Martin PJ, 2004). Myeloid
engraftment is typically expected after two weeks and platelet engraftment 1-2
weeks later (Champlin RE et al., 2000). Adult haematopoietic stem cell transplants,
especially if collected from peripheral blood, engraft earlier than cord blood
transplants (Rubinstein P et al., 1998, Champlin RE et al., 2000).
Chimerism
The level of engraftment of myeloid and lymphoid cells in a patient can be
evaluated by studying chimerism, i.e. the proportion of donor derived cells in the
blood versus cells of patient origin. In these analyses based on molecular
technologies, several differences, e.g. tandem repeats, HLA, gender and blood
groups, can be used (Bryant E and Martin PJ, 2004).
Acute and chronic graft-versus-host disease (GVHD)
Further success of a transplant is related to the occurence and degree of acute
and chronic graft-versus-host disease (GVHD). GVHD is caused by
immunologically reactive T cells in the donor graft, which recognise and attack
host tissues (Korngold R and Sprent J, 1987). Principal target organs of GVHD
are skin, gastrointestinal tract, liver and lymphoid tissue (Glucksberg H et al.,
1974).
Acute GVHD is divided in four grades depending on the extent and severity of
skin rash, serum levels of bilirubin and volume of diarrhea (Thomas ED et al.,
1975b, Przepiorka D et al., 1995).
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Although chronic GVHD with associated immune-deficiency state typically
develops after day 100 of post-tranplantation, the distinction between acute and
chronic GVHD cannot be made solely according to the time from transplantation.
Chronic GVHD commonly involves skin, mouth, liver and eye, and more seldom
the gastrointestinal tract, lungs, oesophagus and joints (Socie G, 2004). The
most commonly used clincal grading system of chronic GVHD is division between
limited (localised skin involvement with or without hepatic dysfunction) and
extensive (generalised skin involvement or limited chronic GVHD and liver, eye,
salivary gland, oral mucosa or other organ involvment) (Shulman HM et al., 1980).
The incidence of GVHD seems lower after cord blood transplantation than
after transplantation with adult haematopoietic stem cells (Rocha V et al., 2001).
Manipulation of the graft
Excess plasma or red cells of a fresh haematopoietic stem cell graft can be
removed in case of blood group discrepancy between donor and the patient
(Saarinen UM et al., 1992, O’Donnell MR, 2004). Graft can also be immunologically
manipulated; e.g. T-cell depletion of adult stem cell grafts is used to diminish
the incidence and severity of GVHD (Ho VT and Soiffer RJ, 2001).
Cord blood which is stored frozen has been protected by DMSO. Practice
varies as to the washing of the transplant immediately prior to transplantation. A
small absolute quantity of DMSO in cord blood may be allowed to other than the
smallest recipients to avoid loss of haematopoietic stem cells (Rubinstein P et
al., 1995, Rowley SD, 2004).
Graft failure
Primary graft failure refers to a situation where engraftment does not happen
and the graft does not start producing new blood cells (Martin PJ, 2004).
Secondary graft failure indicates a situation where the engraftment has taken
place but the function of the graft fails later.
Graft-versus-leukaemia effect (GVL) and donor lymphocyte transfusion (DLT)
Studies on patients with or without GVHD after unrelated adult stem cell
transplantation have suggested that the relapse rate of leukaemia may be higher
in patients with no or milder GVHD. This suggests an antileukaemic effect of
graft, called graft-versus-leukaemia (GVL) effect (Weiden PL et al., 1979, Horowitz
MM et al., 1990). GVL effect, possibly a separate phenomenon from GVHD, has
been elicited by using donor lymphocyte transfusions (DLT), i.e. infusing
immunoreactive lymphocytes collected from the original donor after diagnosis
of a post-transplant relapse (Mackinnon S et al., 1995, Saarinen-Pihkala UM et
al., 2003). After cord blood transplantation this procedure is not applicable, if not
expanding lymphocytes from the small compartment of the unit (Shpall E et al.,
2004 [abstract]).
Outcome research
In addition to using concepts of engraftment, GVHD, graft failure, relapse
(recurrence of the original disease) and transplant related mortality (TRM), the
results of haematopoietic stem cell transplantation studies are analysed using
event-free, disease-free and overall survival (EFS, DFS and OS, respectively).
These refer to the proportion of patients free of disease-related events at certain
24
time points after transplantation (Lee SJ, 2004). Haematopoietic stem cell
transplantation, especially in children, also has long-term consequences on the
quality of life, e.g. diminished fertility (Salooja N et al., 2001) and poorer growth
(Hovi L et al., 1999, Sanders JE et al., 2004).
5.3.2 Bone marrow transplantation
The outcome of bone marrow transplantation can be affected by numerous
variables, e.g. diagnosis, age of the patient, phase of the disease at time of
transplantation, and conditioning treatment.
Based on a large database of more than 16 600 unrelated haematopoietic
transplants facilitated by the National Marrow Donor Program in the USA, 26%,
23% and 19% of transplants have been provided for patients suffering from
chronic myelogenous leukaemia, acute myelogenous leukaemia and acute
lymphoblastic leukaemia, respectively (www.marrow.org/MEDICAL/
distribution.html, October 2004). The most common non-malignant disease has
been severe aplastic anemia in 4% of all transplants. If the transplantation is
perfomed in an early phase of the disease, the five-year survival of adult patients
has been up to 32-43%, depending on the diagnosis (www.marrow.org/MEDICAL/
disease_outcome_data.html, October 2004). Survival after unrelated bone marrow
transplantation is reportedly better in younger patients (McGlave PB et al., 2000),
probably because they tolerate better the intensive treatment accompanying
haematopoietic stem cell transplantation.
An overview of the results of unrelated bone marrow transplantations in children
and adults is presented below (Table 1).
A comparable median time to myeloid engraftment of 18 days has been
reported both in adults and children (Davies SM et al., 2000, Bunin N et al.,
2002). The probability of initial myeloid engraftment – routinely between 90%
and 100% - has not been a clinical problem. Compared with myeloid engraftment,
a slower median time to platelet engraftment (23-32 days) has been reported
(Balduzzi A et al., 1995, Davies SM et al., 2000).
In addition, the probability of platelet engraftment - evaluated from all of the
patients participating in the study - has been only 47-50%, as many of the patients
have succumbed from early transplant related events (Balduzzi A et al., 1995,
Davies SM et al., 2000).
Severe acute grade III-IV GVHD has been reported in 47-49% of patients after
strictly HLA-matched unrelated bone marrow transplantation (Kernan NA et al.,
1993, Balduzzi A et al., 1995). Severe acute GVHD has been reported to be more
frequent with increasing patient age (Kernan NA et al., 1993) and in HLA-
mismatched transplantations (Woolfrey AE et al., 2002). Extensive chronic GVHD
has been reported in 35-39% of patients (Kernan NA et al., 1993, Balduzzi A et
al., 1995, Bunin N et al., 2002).
Vettenranta and collaborators reported less GVHD and more relapses in bone
marrow transplantation recipients who received a T-cell depleted graft compared
with those who received an unmanipulated graft (Vettenranta K et al., 2000). The
authors stated that as the event free survival was similar in the two groups, the
higher risk of transplant related toxic complications in paediatric recipients of
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unmanipulated grafts appears to be balanced by an increased risk of relapse
among recipients of T-depleted grafts.
Three-year disease-free survival of 40-47% in low risk leukaemia and of 10-
19% in advanced leukaemia has been reported (Kernan NA et al., 1993, Balduzzi
A et al., 1995). Unrelated donors offered at least equal five-year event-free survival
compared with sibling donors (54% vs. 39%, respectively) in children with ALL
in second remission (Saarinen-Pihkala UM et al., 2001). In a recent report on
Nordic high risk ALL patients a nine-year event free survival of 61% and overall
survival of 74% were reported (Saarinen-Pihkala UM et al., 2004).
Comparable results have been reported from 62 Finnish children who received
allogeneic bone marrow transplantation between 1974 and 1992 (Makipernaa A
et al., 1995).
5.3.3 Peripheral blood stem cell transplantation
The first succesful peripheral blood stem cell (PBCS) transplantations from HLA
identical sibling donors were reported in 1995 (Bensinger WI et al., 1995, Korbling
M et al., 1995, Schmitz N et al., 1995). Studies comparing allogeneic PBSC
transplantations with bone marrow transplantations are, however, scarce (Schmitz
N, 2004). Ringdén and collaborators compared peripheral blood transplants (N=45)
with bone marrow transplants (N=45) (Ringden O et al., 1999). They reported
faster median myeloid (16 days vs. 20 days) and platelet engraftment (23 days
vs. 29 days) in the PBSC transplant group compared with the bone marrow
transplant group, whereas acute grade II-IV GVHD (30% vs. 20%), one-year TRM
(27% vs. 21%) or overall survival (54% vs. 53%) respectively, did not differ
statistically significantly between the groups. Fast haematopoietic recovery and
relative ease to the donor of stem cell collection have boosted the shift from
bone marrow to PBSC collection, and in 2002 already 54% of allogeneic unrelated
transplantations were performed using PBSCs (Gratwohl A, 2004).
5.3.4 Cord blood transplantation
Transfusion of multiple cord blood samples for the treatment of
lymphangiosarcoma was tried already in the beginning of 1960s with no apparent
effect on the course of the disease (Ende M, 1966). The same authors reported
a transient haematopoietic engraftment in a patient with acute lymphoblastic
leukaemia after a series of eight transfusions of cord blood performed in 1970
(Ende M and Ende N, 1972, Bandini G et al., 2003). In 1974, Knudtzon reported in
vitro growth of granulocytic colonies from human cord blood and suggested the
use of cord blood for restoration of bone marrow function in humans (Knudtzon
S, 1974). After that began the scientific development of the clinical use of cord
blood for haematopoietic reconstitution (Broxmeyer HE et al., 1989, Gluckman E
et al., 1989, Rubinstein P and Stevens CE, 2000).
The first human allogeneic cord blood transplantation was performed in 1988
from a sibling donor to a patient suffering from Fanconi’s anemia (Gluckman E et
al., 1989). The use of related cord blood for transplantation then expanded (Wagner
JE et al., 1995, Rocha V et al., 1998). Successful results were followed by
foundation of the first cord blood banks for storage of unrelated cord blood units
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(Rubinstein P et al., 1994), allowing for the first unrelated cord blood
transplantations to be reported a few years later (Kurtzberg J et al., 1996, Wagner
JE et al., 1996). Recently, favourable results on cord blood transplantation also
to adult patients have been reported (Laughlin MJ et al., 2001, Sanz GF et al.,
2001, Laughlin MjM, 2004, Rocha V et al., 2004).
An overview of the results of allogeneic unrelated cord blood transplantations
is presented in Table 2. No prospective studies comparing cord blood and bone
marrow transplantation have been published until now. Published retrospective
studies have reported parallel results overall for cord blood and bone marrow
transplantation (Grewal SS et al., 2003, Benito AI et al., 2004) (Table 3).
Median times to myeloid engraftment of 22-23 days after cord blood
transplantation have been reported (Kurtzberg J et al., 1996, Wagner JE et al.,
2002), although longer times of up to 32-33 days have also been observed (Locatelli
F et al., 1999, Rocha V et al., 2001). The probability of myeloid engraftment by
day 42 after cord blood transplantation has been 79-89% (Locatelli F et al., 1999,
Thomson BG et al., 2000). Notably, Rubinstein and collaborators reported a clear
positive association between rising dose of infused nucleated cells and incidence
of myeloid engraftment (Rubinstein P et al., 1998).
The median time to platelet engraftment in paediatric patients has been 75-85
days (Locatelli F et al., 1999, Thomson BG et al., 2000). In their early study of 18
patients Wagner and collaborators reported a shorter median platelet engraftment
time of 67 days (Wagner JE et al., 1996), which, however, is still definitively
longer than after stem cell transplants from adult sources. The probability of
platelet engraftment by day 180 after cord blood transplantation has been 65-
85% (Rubinstein P et al., 1998, Wagner JE et al., 2002).
Thus, both the initial incidence and speed of engraftment of myeloid cells and
platelets have been inferior to those of transplants from adult donors if the
matched adult transplantations are directly compared with mismatched unrelated
cord blood transplantations (Laughlin MJ et al., 2004, Rocha V et al., 2004).
Severe acute GVHD has been reported in 9-11% of patients (Thomson BG et al.,
2000, Wagner JE et al., 2002), although a higher incidence (23%) has been
reported by some authors (Locatelli F et al., 1999, Rubinstein P et al., 1998).
Data on the incidence of chronic GVHD vary; the condition having been reported
in 9.5-28% of patients (Kurtzberg J et al., 1996, Rubinstein P et al., 1998, Locatelli
F et al., 1999). A 9% incidence of extensive chronic GVHD was observed by
Wagner and collaborators (Wagner JE et al., 2002), while some authors have not
detected chronic GVHD at all (Gluckman E et al., 1997, Thomson BG et al., 2000).
The probability of severe acute GVHD after cord blood transplantation has
remained lower than after stem cell transplantion from adult sources, despite
HLA incompatibilities of 1-3 mismatches out of six in a substantial proportion of
cord blood transplantations (Rocha V et al., 2001).
In their large study of 562 unrelated cord blood transplantation recipients,
Rubinstein and collaborators reported a 46% incidence of transplantation-related
events by day 100 (Rubinstein P et al., 1998). Treatment-related mortality at one
year after transplantation has been 20-30% (Thomson BG et al., 2000, Wagner
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JE et al., 2002), although an incidence of 52% has also been reported (Locatelli
F et al., 1999). In recent studies, overall survival at one year has been 52-58%
(Thomson BG et al., 2000, Wagner JE et al., 2002).
Seven related and seven unrelated cord blood transplantations have been
reported in the Children’s Hospital in Helsinki, with an overall survival of 78.5%
(Vettenranta K, 2004, personal communication). Six of these transplants have
been reported earlier (Vettenranta K et al., 1997a, Vettenranta K, 2000). Two of
the five patients received three unrelated cord blood transplantations, in which
the time to myeloid engraftment was 23-35 days, and the time to independency
of platelet transfusions 16-55 days.
In cord blood transplantation studies patients without a compatible sibling or
unrelated adult donor have received transplanted cord blood with the best
available HLA match often as a last resort. A higher degree of HLA disparity
between patient and cord blood transplant has been associated with lower
incidence of myeloid and platelet engraftment and slower recovery (Gluckman E
et al., 2004), as well as with elevated transplant-related events (Rubinstein P et
al., 1998). HLA disparity in cord blood transplantations has been more a rule
than an exception, as the total number of cord blood transplants available in
banks is still less than 200 000 compared with more than 9 000 000 unrelated
donors in registries (http://www.bmdw.org/Database/Donors.htm, September
2004). Patients with varying malignant and non-malignant diseases have also
been analysed together, and as cord blood transplantation has been used as a
second alternative for bone marrow transplantation, patients in studies have
represented more advanced phases of disease (Rubinstein P et al., 1998).
Conditioning regimens have varied between transplant centres as well (Rocha V
et al., 2001). The main problem in cord blood transplantation has been slower
engraftment of the platelet compartment than in bone marrow transplantation;
however, in favour of cord blood is the reported lower incidence of acute and
chronic GVHD (Madrigal JA et al., 1997, Rocha V et al., 2000) and better tolerance
of HLA mismatch between patient and cord blood unit (Rubinstein P et al., 2001
[abstract]).
Haematological recovery after cord blood transplantation
The delayed haematopoietic recovery observed with cord blood compared to
bone marrow transplantation may be due to the intrinsic difficulty of cord blood
cells to undergo differentiation. Frassoni and collaborators reported higher
frequency of CFU and LTC-IC colonies in the bone marrow of children who had
received cord blood transplantation a median time of one year earlier compared
with those who had received bone marrow tranplantation, although the
transplanted bone marrow cellular dose was 1-log higher (Frassoni F et al., 2003).
Cord blood haematopoietic stem cells may thus provide for a better
haematopoietic reconstitution.
Immunological recovery after cord blood transplantation
Although higher early mortality (<100 days) after cord blood transplantation from
bacterial and viral infections compared with bone marrow transplantation has
been reported (Rocha V et al., 2001), immunological recovery after cord blood
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transplantation may exceed that after bone marrow transplantation. Talvensaari
and collaborators reported higher T-cell receptor diversity and T-cell receptor
rearrangement excision circle (TREC) values, an ex vivo measure of thymic
function, two years after cord blood transplantation compared with bone marrow
transplantation (Talvensaari K et al., 2002). Human foetal and cord blood
lymphocyte progenitors also have similar potential to those of adult blood for
generating B cells with a diverse immunoglobulin repertoire (Kolar GR et al.,
2004). These studies suggest that, although immunologically naive, cord blood
cells are likely to have a great potential to fully reconstitute the immune system.
GVL effect after cord blood transplantation
Cord blood transplantation probably elicits an adequate graft-versus-leukaemia
(GVL) effect, as relapse rates in clinical studies have not been unusually high as
was earlier feared (Rubinstein P et al., 1998, Gluckman E and Rocha V, 2004,
Broxmeyer HE, 2004).
Experimental cord blood transplantation
Multiple cord blood transplantation. To overcome the low cell dose in an average
cord blood unit, infusion of multiple cord blood units has been studied. However,
early and more recent studies on multiple cord blood unit transfusion have yielded
only transient improvements (Ende M, 1966, Ende M and Ende N, 1972, Shen BJ
et al., 1994, Weinreb S et al., 1998). Infusion of leukocytes to treat life-threatening
infections after profound post-transplant neutropenia has been reported to yield
prompt and sustained myeloid recovery (Saarinen UM et al., 1995).
Co-transplantation of third-party haploidentical mobilised peripheral blood CD34+
cells with an unrelated cord blood unit has also been reported to enhance
engraftment, thereby shortening post-transplant neutropenia (Fernandez MN et
al., 2004 [abstract]). These results suggest a boosting mechanism, possibly
cytokine mediated, in the haematopoietic stem cell milieu.
More recently, double cord blood transplants have been shown to yield inital
double chimerism of the recipient (Barker JN et al., 2001b, De Lima M et al.,
2002). Barker and collaborators reported a low incidence of severe GVHD (15%)
and TRM (23%) in high-risk adults receiving 11 single and 29 double cord blood
unit transplantations, with no significant differences in transplant outcomes
between single and double unit recipients (Barker JN et al., 2004 [abstract]).
Although both transplanted units initially engrafted, it was not possible to predict
by the amount of transplanted nucleated or CD34+ cells, or by the HLA match,
which of the units was responsible for long-term haematopoietic reconstitution.
Interestingly, a higher CD3+ cell dose in the predominating cord blood unit has
been reported recently (Barker JN et al., 2005). These promising results suggest
that combining two units may render cord blood satisfactory for larger proportion
of patients requiring stem cell transplantations, especially for adult patients.
Ex-vivo expansion. CD34+ selection and expansion of cord blood haematopoietic
progenitor and stem cells in the laboratory has been extensively studied for use
in gene therapies as well as to facilitate provision of adequate cell doses for
transplantation for adult patients (Traycoff CM et al., 1995, Dorrell C et al., 2000,
Shpall EE et al., 2004). Expanded cells are now infused together with the non-
expanded part of the graft, thus proving the safety of the procedure.
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Other stem cells. As cord blood has become accepted as a source of
haematopoietic stem cells, also presence of stem cells of other cell lineages
has been explored. Recently, multipotent mesenchymal stem cells capable of
differentiating into cell types of all three germ layers have been detected in cord
blood (Lee OK et al., 2004). Also, studies on differentiating cord blood
mesenchymal cells into e.g. neural or muscle cells are under way (Bicknese AR
et al., 2002, Gang EJ et al., 2004).
Potential problems with cord blood
Small cell content. Although cord blood has been used with success in allogeneic
haematopoietic reconstitution even in adult patients (Laughlin MJ et al., 2001),
the majority of currently available cord blood units contain relatively low total
nucleated cell numbers (Oudshoorn M and Foeken-van Goozen L, 2004), possibly
inadequate for transplantations as single units. Recently, promising results using
two cord blood units from different allogeneic unrelated donors have been
reported (Barker JN et al., 2005).
Single dose. Compared with the possibility of a donor lymphocyte transfusion in
case of relapse after adult donor haematopoietic stem cell transplantation (Dazzi
F et al., 2000), after cord blood transplantation haematopoietic or other cells
from the same donor are not available. However, cord blood banks may have
frozen the unit in more than one compartment, enabling separate future use.
Possibilities to expand specific cell populations from cord blood, e.g. NK cells or
cytotoxic T-lymphocytes, are being explored (Ayello J et al., 2004 [abstract],
Satwani P et al., 2004 [abstract]).
Maternal cell contamination. Maternal cells may contaminate infant blood due
to transplacental cell transfer (Schroder J and de la Chapelle A, 1972). Scaradavou
and collaborators reported 38% of cord blood collections positive for maternal
DNA (Scaradavou A et al., 1996). Recently, minor H antigen HA-1 specific T-cells,
potentially supporting the GVL effect, have been detected in cord blood
(Mommaas B et al., 2004). Cord blood standards do not require testing of units
for maternal cell contamination (NETCORD and FAHCT, 2001), and neither has
maternal cell engraftment been a problem in cord blood transplantation.
Origin of leukaemia. The aetiology of leukaemia remains largely unknown.
Identification of chromosome translocations in neonatal blood spots of later
identified leukaemia patients has led to the suggestion that childhood ALL is
frequently initiated in utero (Wiemels JL et al., 1999). Infant leukaemia is, however,
a rare disease (Biondi A et al., 2000). In addition, a cord blood unit is re-evaluated
if information concerning the usability of the unit for tranplantation purposes is
obtained.
5.4 Cord blood banking and networks
The probability of finding a related or unrelated haematopoietic stem cell donor,
despite the huge number of nine million or more stem cell donors in international
registries, is only approximately 50-75% (Confer DL, 1997). Thus, additional
sources for haematopoietic stem cells are needed. Since the first successful
human transplantation of cord blood (Gluckman E et al., 1989), cord blood banks
have been established world wide during the 1990s (Rebulla P, 2002).
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In principle, cord blood is abundantly available, being a byproduct of delivery
and considered as a waste material. The genetic background of any population
may be well represented in a cord blood bank. Once identified and subjected to
additional testing in a bank, a cord blood transplant can be shipped frozen to the
transplant centre with minimal delay. Most banks collect cord blood from healthy
volunteer donor mothers with no remuneration for use in unrelated allogeneic
tranplantation.
Cord blood may be collected as a directed cord blood unit after the birth of a
healthy sibling. The unit may then be stored in a bank if there is already an
affected sibling in need of possible cord blood transplantation in the family (Reed
W et al., 2003). Hospitals may also take care of banking of the directed cord
blood unit.
In a commercial setting cord blood can be cryopreserved, even without a
family disease history, in case of a possible future autologous or allogeneic need
– albeit extremely improbable – for haematopoietic stem cell reconstitution
(American Academy of Pediatrics. Work Group on Cord Blood Banking, 1999).
Autologous and directed, as well as commercial cord blood banking, are not
further discussed in this review.
5.4.1 Quality management systems
The importance of implementing good manufacturing practice (GMP) and quality
systems in blood banking was emphasized in mid 1990s. The cord blood
community has developed standard policies and procedures to enable and
improve both evaluation of the quality of cord blood transplants and of clinical
cord blood transplantation results (Fraser JK et al., 1998, American Association
of Blood Banks, 2001). Other quality systems have also been adapted in cord
blood banking, as reported by Sirchia and collaborators (ISO) (Sirchia G et al.,
1998b, Sirchia G et al., 1998a) and Armitage and collaborators (GMP/GLP)
(Armitage S et al., 1999b). Netcord/FAHCT standards (www.unmc.edu/
Community/fahct), adopted by the European Group for Blood and Marrow
Transplantation (EBMT) and the World Marrow Donor Association (WMDA),
among many organisations, specify detailed requirements for the whole cord
blood banking process from donor recruitment through collection, processing,
banking and testing to selection and release of a cord blood unit for clinical use
(NETCORD and FAHCT, 2001). These standards require all cord blood bank policies
and processes be defined in detail as written standard operational procedures
(SOP).
5.4.2 Safety aspects of the cord blood transplant
Recruiting and selecting the donor mother
In cord blood banking programmes, mothers are routinely informed about the
possibility of donating cord blood during the antenatal period (Navarrete C et al.,
1998). The aim of this phase of recruiting is to ensure safe transplants by
preselecting healthy mothers for donation.
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Medical history and maternal blood sample
The mother is interviewed using a standard questionnaire covering the personal
and family history of genetic diseases, malignancy, transmittable infectious
diseases and autoimmune diseases, as well as disorders of unknown aetiology
(Armitage S et al., 1999b). Netcord/FAHCT standards require each cord blood
donor mother to be tested for anti-HIV-1/2, HIV-1-Ag (or HIV-NAT), anti-HTLV-I/II,
HBsAg, anti-HBc, anti-HCV, and a serological test for syphilis (NETCORD and
FAHCT, 2001). A cord blood unit sample also has to be tested for any additional
required future infectious disease markers prior to release for transplantation.
The maternal blood sample is drawn as part of the informed consent process
(Armitage S et al., 1999b).
It is obvious that the infectious tests required will increase in number as new
diseases appear. Archived samples are stored to allow for future tests, e.g.
genomic testing for inherited diseases, during long-term storage of the cord
blood unit. Once stored, the evidence of safety of cord blood units can be
accumulated, contrasted to living stem cell donors.
5.4.3 Cord blood collection
Informed consent
Informed consent may be obtained orally before cord blood collection and
complemented in written after successful collection (Armitage S et al., 1999b).
The collections can also be directed only to mothers who have given full consent
beforehand and who fullfill the predefined collection criteria (Elias M et al., 2003).
However, as a marked proportion of cord blood collections is known not to yield
adequate volume for further use, in this model a substantial effort is wasted
overall in the labour intensive consent process.
Collection principles of cord blood
In contrast to the risks associated with bone marrow and blood stem cell
collections, cord blood ex utero collection methods pose no risk to the donor
mother or infant (Fasouliotis SJ and Schenker JG, 2000, Fasouliotis SJ and
Schenker JG, 2000). Cord blood banks perform routinely a high number of
collections, a substantial portion of which are not acceptable for further storage
due to e.g. low collection volume, low cell content or adverse medical history of
the mother (Armitage S et al., 1999b).
Several methods of collecting cord blood were analysed during the
development of cord blood banking programmes in the early 1990s (Wagner JE
et al., 1992, Hirsch I et al., 1993, Harris DT et al., 1994, Bertolini F et al., 1995).
Open collections where cord blood was drained from the dissected cord directly
into a container or aspirated by syringes were associated in elevated rate (12.5%)
of bacterial contamination compared with closed collections (3.5%) using
standard sterile closed blood collection bag sets (Bertolini F et al., 1995). An
aseptic technique is important in cord blood collection: rates of bacterial
contamination have diminished from 28% to 4% with accumulating experience
(Armitage S et al., 1999b), and even lower contamination rates are possible.
Cord blood collections are performed either by trained cord blood bank
personnel or delivery unit midwives or obstetricians (Wall DA et al., 1997). Blood
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can be collected while the placenta is still in utero, or ex utero after the birth of
the placenta in a separate collection area (Lasky LC et al., 2002). After the infant
is born the umbilical cord is double clamped and dissected. The umbilical vein is
then cannulated and, to avoid haemolysis, cord blood is drawn by gravity into
the collection bag, where it is continuously mixed with the anticoagulant
(Donaldson C et al., 2000).
Although several obstetric practices, e.g. positioning the infant before clamping
of the umbilical cord, and timing of clamping, affect the obtained cord blood
volume and cell contents, attempts to modify the course of delivery in order to
increase the cellular yield in cord blood collections are currently not accepted.
Also, especially in unrelated setting, in utero collections may be experienced as
more disturbing than collections after the placenta is born.
5.4.4 Selection of cord blood collections for banking
Cord blood volume obtained from the umbilical vein during collection may vary
between 0 and 255ml depending on the collection technique and mode of delivery
(Armitage S et al., 1999b, Donaldson C et al., 2000, Elchalal U et al., 2000). Banks
routinely use a cut-off limit of collected cord blood, e.g. 40ml, to increase the
cell yield available for banking (Armitage S et al., 1999b). Depending on the
selected cut-off limit, an average collected cord blood volume reported has been
68-107ml (Wall DA et al., 1997, Armitage S et al., 1999b, Donaldson C et al.,
2000, Lasky LC et al., 2002).
Collected total cell amount naturally also varies according to the collected
volume. Total nucleated cell counts, such as 102-169 *107/unit, have been reported
(Armitage S et al., 1999b, Lasky LC et al., 2002, Wall DA et al., 1997, Elchalal U et
al., 2000), which may reflect the actual cut-off limits set for collected volume
and nucleated cell concentrations analysed by the individual banks (Eichler H et
al., 2004).
5.4.5 Short-term liquid storage of cord blood before processing
Maintaining the quality of cord blood during transport from collection site to the
laboratory and at the laboratory before processing is of utmost importance. In
particular, fluctuations in temperature before long-term storage have to be
minimised (NETCORD and FAHCT, 2001).
When cord blood storage in +4°C or +22°C was compared, 88-93% of CD34+
cells, 85-95% of CFC and 89-91% of CAFC were viable at 48 hours in either
temperature (Bertolini F et al., 1998). Storing of cord blood at +4°C or +22°C
resulted in comparable recoveries of CD34+ cells and nucleated cells at 72 hours
. Neither did storing cord blood for 24 hours before cryopreservation adversely
influence the post-thaw cell recovery of nucleated cells, CD34+ cells or CFC
(Hubel A et al., 2003).
Most collection facilities are located near the processing laboratory, but
transporting the cord blood from remote locations has also produced adequate
results (Wada RK et al., 2004). Cord blood can be placed between
thermoregulatory elements (e.g. pre-chilled whole blood bags) and the
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temperature of the shipment may be electronically monitored throughout
transport (Hubel A et al., 2004). Thus, as long as the ambient conditions are
carefully monitored, cord blood can be stored cooled or at room temperature
(+17°C - +20°C) before processing, although the risk of bacterial growth may
increase during storage at higher temperatures.
Liquid storage of cord blood for other usages
Blood bank stored cord blood was used in allogeneic blood transfusions as far
back as the 1930s (Halbrecht J, 1939). More recently, cord blood has also been
studied for autologous transfusion in preterm infants to correct anaemia (Surbek
DV et al., 2000a, Eichler H et al., 2000). As cord blood contains haematopoietic
progenitor and stem cells, the feasibility of blood bank stored liquid cord blood
for haematopoietic reconstitution in undeveloped countries has been studied
(Ende N et al., 1999). However, the established practice for long-term maintenance
of cord blood haematopoietic stem cells is storage in the frozen state (see Section
5.4.7).
5.4.6 Processing: whole blood and volume reduction of cord blood
As storage of thousands of cord blood collections as whole blood would require
substantial additional economic resources for greatly increased freezer capacity,
methods to reduce the volume of the collection still maintaining the
haematopoietic stem cell content have been studied (Harris DT et al., 1994,
Denning-Kendall P et al., 1996, Bertolini F et al., 1996). In 1995, Rubinstein and
collaborators published their widely adapted volume reduction protocol involving
two sentrifugation phases (Rubinstein P et al., 1995). In the first phase, the red
cell sedimentation rate is enhanced by adding hydroxyethyl starch to the cord
blood prior to centrifugation. The separated leukocyte and platelet rich supernatant
with the haematopoietic stem cells is further centrifuged and excess plasma is
removed to obtain a cord blood unit of exactly desired volume (Rubinstein P et
al., 1995).
Another volume reduction protocol adapted by cord blood banks uses the
triple bag system, a so called top-and-bottom bag in which, after centrifuging,
red cells and excess plasma are extracted in one step leaving the buffy coat
layer containing the haematopoietic stem cells in the original bag (Armitage S et
al., 1999a). In this system, adjusting the end volume has been problematic.
Using these methods, recoveries of up to 91-92% of nucleated cells have
been reported on experimental scale (Rubinstein P et al., 1995, Armitage S et al.,
1999a). Several other technical solutions to separate the cord blood leukocyte
fraction are also being developed.
5.4.7 Cryopreservation
Since cryopreservation is the only feasible method for long-term storage of cord
blood haematopoietic stem cells, and as the number of cells in a given collection
is limited, it is of the greatest importance that the cryopreservation protocol
optimises cell recorery, viability and function (Armitage S, 2000). Cord blood
megakaryocytic progenitor cells have been reported to be more sensitive to the
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stresses of cryopreservation than the respective myeloid progenitor cells (Xu Y
et al., 2004). Cord blood cryopreservation techniques have been adapted from
those developed for bone marrow and peripheral blood stem cells (Rowley SD,
1992, Donaldson C et al., 1996). Recently, theoretically optimised methods to
improve cryopreservation protocols have been developed (Woods EJ et al., 2003).
A crucial issue in tissue cryopreservation is controlling the formation of ice crystals
during freezing. At rapid rates of cooling intracellular ice crystals may form,
resulting in mechanical cell injury. At slow cooling rates ice crystal formation
tends to occur in extracellullar space, resulting in increased osmolality as free
water is incorporated in growing ice crystals. Extreme extracellular
hyperosmolality may then lead to dehydration injury (Rowley SD, 2004). Controlled-
rate freezing profiles aim to minimise the formation of ice crystals.
Cryoprotection
The increase of the osmolality and the effect of that increase on cells are controlled
by adding cryoprotectant solutions to the cord blood unit before cryopreservation.
The cryoprotectant properties of dimethylsulfoxide (DMSO) were described
already in 1959 (Lovelock JE and Bishop MW, 1959). DMSO is the favored agent
for cryopreservation of haematopoietic stem cells because of its rapid diffusion
through the cell membrane and relative non-toxicity during infusion to patients
(Takahashi T et al., 1985, Rowley SD, 2004). The optimal concentration of DMSO
for cryoprotection of haematopoietic stem cells is approximately 10%,
concentrations of 5%-15% having been studied. Macromolecular non-penetrating
cryoprotectants, such as hydroxyethyl starch (HES) and dextran, as well as protein
solutions, have been studied in haematopoietic stem cell cryopreservation,
especially in combination with penetrating cryoprotectants. However, studies
comparing DMSO alone or in combination with e.g. HES in cryopreservation of
haematopoietic stem cells are scarce (Rowley SD, 2004).
Characterisation of a cord blood transplant prior to cryopreservation
Several laboratory samples have to be taken from the cord blood unit for to
analyse its cellular composition and haematopoietic potential and for HLA typing
for matching purposes (NETCORD and FAHCT, 2001). As the volume of a cord
blood collection is restricted, the sample volume is kept at a minimum and
sampling of the side products of the process (plasma, residual nucleated cells in
red cell fraction) are used when applicable. A haematology analyser is used to
analyse samples for full blood count and differential (Section 5.1.2.1). A smear
can be prepared and stained for later analysis, e.g. of nucleated red cells. CD34+
cells (5.1.2.3) and haematopoietic progenitor cells are also enumerated (5.1.2.2),
and aerobic and anaerobic microbiological cultures taken (Armitage S et al.,
1999a).
Controlled-rate freezing
Freezing the cord blood unit using a rate-controlled programmed freezer has
been widely adopted by cord blood banks to provide maximum protection for
haematopoietic stem cells (Armitage S, 2000). To protect the primary storage
bag from breakage, it is enclosed in a metal canister for freezing. The optimal
cooling rate depends on the cell type and on the concentration of cryoprotectant.
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For human haematopoietic stem cells suspended in 10% DMSO, an optimal
freezing rate of 1-3°C/minute has been reported (Ma DD et al., 1982). After initial
freezing of water, higher cooling rates may be used (Rowley SD, 2004). Although
controlled-rate freezing is preferred by the majority of cord blood banks, parallel
results using insulating material to protect the cord blood unit have been reported
when the unit has been damped to -80°C freezer and after passive freezing
transferred to -196°C for further storage (Itoh T et al., 2003). After controlled-rate
freezing in a separate device, the canister is transferred to another container for
long-term storage. To avoid transient warming events (Dobrila L et al., 2001
[abstract]) during the transfer of frozen cells between two tanks, automated
robotic devices where both controlled-rate freezing and long-term storage take
place in the same device can be used (e.g. BioArchive, Thermogenesis, Rancho
Cordova, CA).
Long-term storage
Cord blood haematopoietic stem cells are stored either in mechanical electric
freezers or in the liquid or vapour phase of nitrogen below –135°C to prevent
possible progressive growth of ice crystals, as water migrates form smaller to
larger crystals at warmer freezing temperatures (Rowley SD, 2004).
Liquid phase of nitrogen (-196°C) provides the most stable environment for
long-term storage and is regarded safest, as temperature changes in the vapour
phase of up to 100°C have been reported (Rowley SD and Byrne DV, 1992).
Contamination with hepatitis B virus of the liquid phase of nitrogen in a
cryopreservation tank has been reported (Tedder RS et al., 1995). Microbial
contamination is also possible in the vapour phase of nitrogen (Fountain D et al.,
1997). Thus, cord blood haematopoietic stem cell units should be either quarantine
stored before transfer to the main tank or double bags should be used to protect
the unit and reduce the risk of contamination of the nitrogen tank (Khuu HM et
al., 2002).
Cryopreservation of cord blood in liquid nitrogen of at least six months as
whole blood or separated mononuclear cells did not impair the clonogenic
capacity of haematopoietic stem cells (Almici C et al., 1997). Harris and
collaborators reported only minimal effects of cryopreservation of seven years
on the ability of cord blood cells to become cytotoxic effector cells when
stimulated with interleukin-2 (Harris DT et al., 1994). Broxmeyer and collaborators
studied the quality of cord blood samples after extended storage. They reported
immature cord blood cells stored frozen for 15 years with high proliferative,
replating, ex vivo expansion and NOD/SCID mouse engrafting ability (Broxmeyer
HE et al., 2003). Also, cord blood CFU-GM, CFU-GEMM and BFU-E recovery
rates of more than 97% have been reported after storage for up to 12 years
(Mugishima H et al., 1999). Thus, cord blood units probably remain effective for
clinical transplantation after long-term frozen storage.
After review of clinical, processing and laboratory data against predefined
acceptance criteria, cord blood units are entered in international search registries
(Section 5.4.9).
Transportation in frozen state
The temperature should be maintained at -135°C or below during the
50
transportation of the cord blood unit from bank to transplant centre (NETCORD
and FAHCT, 2001). For this purpose “dry shippers” can be used. In these devices
liquid nitrogen is absorbed into the wall of the container, enabling a stable
environment below –135°C in the container for 7-10 days (Rowley SD, 2004).
5.4.8 Thawing
Only minor to moderate infusion-associated adverse reactions have been
described during infusion of haematopoietic stem cell grafts (Davis JM et al.,
1990). Thus, haematopoietic stem cells are often infused without removing
DMSO, as the removal procedure has been feared to hamper the haematopoietic
quality of the product. As the storage procedures and conditions have been
optimised for mononuclear cells, thawing of the unit yields lysis of the neutrophils
and red cells (Rubinstein P et al., 1995).
Reducing the DMSO content of a cord blood unit after thawing by diluting
and washing the cell suspension one or more times with human albumin and
dextran solution has been suggested to improve the cord blood cell viability
(Rubinstein P et al., 1995). Although post-thaw total leukocyte yields of non-
washed and washed cord blood units did not differ (94% and 92%, respectively),
the post-thaw yields of viable leukocytes in the study of Rubinstein and
collaborators were 35% and 61%, respectively. However, in one study, wash-out
of the DMSO did not improve the speed of engraftment after cord blood
transplantation (Nagamura-Inoue T et al., 2003).
Even when the cell yields are optimised, washing may cause a certain loss of
cells and might also hamper their viability, especially if validated devices and
procedures are not in use. CD34+ cell and CFU yields exceeding 100% are seen
(Armitage S et al., 1999a), possibly because of cell activation. Correct identification
of the cord blood unit throughout the thawing procedure using unique numbers
is also important (such as e.g. ISBT 128, ICCBBA Inc) (Ashford P, 2002).
5.4.9 Cord blood banks and networks
The first cord blood bank was established in New York Blood Center by Dr Pablo
Rubinstein in February 1993 (Rubinstein P et al., 1994) (National Cord Blood
Program). Cord blood banking programmes have since been initiated at several
places in United States (Alonso JM, III et al., 2001, Lasky LC et al., 2002), Europe
(Lazzari L et al., 1996, Querol S et al., 1998, Navarrete C et al., 1998, Dal Cortivo
L et al., 1998, Jacobs HCJM and Falkenburg JHF, 1998, Pojda Z et al., 1998,
Armitage S et al., 1999b, Kogler G et al., 1999, Ordemann R et al., 1999, M-
Reboredo N et al., 2000, Donaldson C et al., 2000, Rendine S et al., 2000, Proctor
SJ et al., 2001), Australia (Vowels MR and Lam-Po-Tang PR, 1997) and Asia
(Mugishima H et al., 2002, Lee TD, 2002, Elias M et al., 2003, Wacharaprechanont
T et al., 2003). Forty cord blood banks or registries in 24 countries participate in
WMDA (Oudshoorn M, Foeken-van Goozen L, 2004).
To enable an HLA type-based search of donors from bone marrow and
peripheral blood stem cell donor registries across the world, Bone Marrow Donors
Worldwide (BMDW) was established by EBMT (Oudshoorn M et al., 1994). BMDW
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relased its first listing of 156 000 donors in February 1989. Currently, more than
9 million potential donors are listed. Large national registries in the USA, e.g. the
National Marrow Donor Program (www.nmdp.org) and the Caitlin Raymond
International Registry (www.crir.org), also participate in BMDW. Although BMDW
was first established to allow for international searches of tissue typed adult
donors, cord blood units are also currently listed. At present, 37 cord blood
registries in 21 countries (with a total of 172 550 cord blood units) participate in
BMDW (www.bmdw.org/Database/Donors.htm, as of July 2004).
Netcord, founded in May 1998, is an international non-profit joint effort of
leading cord blood banks which has issued statutes and guide-lines with the
primary aim of improving the quality of cord blood transplants for clinical cell
therapy on the international level (Wernet P et al., 2001 [abstract], NETCORD
and FAHCT, 2001) (www.unmc.edu/Community/fahct). To enable efficient cord
blood unit data exchange and allocation, the Netcord inventory is available for
searches in a virtual office via the internet (office.de.netcord.org). In addition,
cord blood banks in Asia are now associated under the name of Asiacord
(Mugishima H et al., 2002).
To enable coordinated management of complicated international
haematopoietic stem cell donor search processes, search activities in each
country have been centralised to national hubs.
5.4.10 Ethics
Ethical issues surrounding the developing cord blood banking technology and
practices have been addressed (Lind SE, 1994). Among other matters, the
obligation to notify parents and children of positive results of testing for infectious
diseases has raised some discussion (Sugarman J et al., 1995). The need to
maintain linkage between the donor and the banked cord blood has also been
debated (Sugarman J et al., 1997). In the US, a policy of not maintaining the
linkage between cord blood donor mother identity and donated cord blood
information has been applied earlier (Rubinstein P et al., 1994). According to the
Netcord/FAHCT standards the linkage has to be maintained (NETCORD and
FAHCT, 2001). Another issue is whether unrelated in utero cord blood collections
interfere with the labour process to such a degree that it should be considered
unethical. Delivery practices are not routinely modified by any means in order to
increase the collected cord blood volume. Moreover, the newborn is not touched
at all and no blood sample is taken from him/her. All blood samples needed for
infectious disease testing are drawn from the volunteer mother.
In the ideal informed consent process, persons who have adequate decision-
making capacity are given accurate and relevant information about the risks,
benefits and alternatives of a proposed intervention. They then use this
information to make a voluntary decision about the intervention that is consistent
with their own values (Sugarman J et al., 1997). The quality of the informed
consent procedure has been discussed as well; even if it fullfills the current
ethical requirements, the procedure needs continuous optimisation regarding
the donor mother’s need for information (Sugarman J et al., 2002).
52
5.5 Cord blood transplant
Several gestational as well as mother- and infant-related factors have been
reported to affect both the cord blood quality and cell contents, although total
cell counts have mainly been used in analyses (Shlebak AA et al., 1998, Donaldson
C et al., 1999, Ballen KK et al., 2001, Jones J et al., 2003).
5.5.1 Birth weight of donor infant
Foetal growth and birth weight standards
Human growth is a complicated process characterised by numerous unique
features, including extremely rapid foetal growth which slows down immediately
after birth (Rosenfeld RG, 2003). Specific growth standards are needed to evaluate
birth weight as an indicator of intrauterine growth. As male fetuses weigh more
than female, at least from the 35th week of gestation on, growth standards have
to be applied to gender (Tanner JM and Thomson AM, 1970). Also, as the varying
genetic background of populations and multiple geographical and social factors
affect birth weight (Gruenwald P, 1966), the standards need to be population-
specific (Pihkala J et al., 1989, Arbuckle TE et al., 1993). Birth weight data sets
are, however, cross-sectional by nature and, at a given gestational age, births
are not a random sample of all intaruterine fetuses. Classifications such as “small
for gestational age” (SGA) and “large for gestational age” (LGA) have been
traditionally defined as infants below the 10th or above the 90th percentile,
respectively, at each gestational age, and the term intrauterine growth retardation
(IUGR) has been used almost as a synonyme for SGA (Wilcox AJ, 2001). There
has also been considerable variance as to how macrosomia (too high a birth
weight for the gestational age and gender) has been defined.
Birth weight, which depends both on gender and gestational age, can be
analysed using a standardised deviate (z score) (Oken E et al., 2003). The standard
normal distribution (z distribution) is a normal distribution with a mean of 0 and
a standard deviation of 1. Any point (x) from a normal distribution can be converted
to the standard normal distribution (z) with the formula z = (x-mean) / standard
deviation. Z for any particular x value shows how many standard deviations x is
away from the mean for all x values (Armitage P et al., 2002). Thus, a birth
weight z score (relative birth weight) of 0 for a child indicates that the birth
weight of that child is exactly as expected regarding the gestational age and
gender of that child. Correspondingly, a relative birth weight of 1 indicates that
the birth weight of that child is one standard deviation higher than its gestational
age and gender-specific expected weight.
Although the actual level of accuracy in predicting birth weight is far from that
described theoretically above, higher birth weight has been reported to yield
higher total nucleated and CD34+ cell amounts in cord blood collections (Ballen
KK et al., 2001), whereas the relationship between cord blood CD34+ cell
concentration and birth weight has not been described.
Placental weight
The relationships between placental weight, birth weight and obstetric factors
have been studied for decades (Sedlis A et al., 1967, Friedman EA and Sachtleben
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MR, 1969). Placental weight and birth weight correlate positively (Courcy-Wheeler
R and Wolfe C, 1992, Altman DG et al., 1992). Higher placental weight has also
been reported to correlate positively with collected cord blood volume (Jones J
et al., 2003).
Maternal diabetes
Studies on possible associations between maternal diabetes and cord blood
quality are scarce. As the ideal intrauterine growth potential of an individual is
not known, a registered ‘normal’ birth weight may even reflect abnormal
(pathological) growth, especially in diabetic pregnancies (Schwartz R and Teramo
KA, 1999).
Gestational diabetes predisposes the newborn infant to macrosomia (Schwartz
R et al., 1994). Two-thirds of women diagnosed with gestational diabetes using
oral glucose tolerance test are treated only by diet (Suhonen L and Teramo K,
1993) and could thus participate in a cord blood banking programme. As birth
weight correlates with the collected cord blood volume (Jones J et al., 2003),
cord blood collections from gestational diabetic pregnancies would be expected
to yield higher total cell counts.
Gender
Differences between female and male fetuses are traditionally thought to originate
under estrogen and androgen hormonal influence during pregnancy (Dennis C,
2004). Recently, however, differences in gene expression of early female and
male mice fetuses have been reported before gonadal influence (Dewing P et
al., 2003).
Studies on the effect of gender on haematopoietic stem cells are scarce.
Female infants have been reported to have higher cord blood nucleated cell total
content (Ballen KK et al., 2001) and concentration (Nakagawa R et al., 2004).
5.5.2 Obstetric factors
Gestational age
The haematopoietic progenitor cell content of cord blood reportedly diminishes
during pregnancy. Cord blood CFU-GM concentration in infants born after 25-31
weeks of gestation was 10/µl compared with 3.8/µl and 3.0/µl in infants born
after 32-36 and 38-41 weeks of gestation, respectively (Clapp DW et al., 1989).
BFU-E colonies have been found three-fold (160/105 cells vs. 48/105 cells) (Forestier
F et al., 1991) and seven-fold (484/105 vs. 69/105 cells) (Jones HM et al., 1994)
higher in second trimester foetal blood compared to term cord blood.
CD34+ cell content as percentage of lymphocytes (and as concentration) has
been reported to diminish from a mean of 11.1% (9.2*107/l) at 13 weeks of
gestation to 1.0% (3.0*107/l) at 38 weeks (Thilaganathan B et al., 1994b). Surbek
and collaborators reported a significantly higher relative CD34+ cell content in
second trimester compared to term cord blood (2.57% vs. 0.7%, respectively)
(Surbek DV et al., 1998). Parallel results were obtained by Shields and Andrews,
who reported a 4.9-fold higher frequency of CD34+ cells in early foetal blood at
17-24 weeks of gestation compared with that at term (6.4% vs 1.3%, respectively).
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The frequency of CD34+ cells in their study also declined linearly with gestational
age (Shields LE and Andrews RG, 1998).
In contrast, leukocyte concentration has been reported to increase from 18th
week of gestation to term (Clapp DW et al., 1989, Forestier F et al., 1991).
Factors related to delivery
Stress during delivery has been associated with elevated cell numbers in cord
blood. In a univariate model, Lim and collaborators observed that a prolonged
first stage of labour resulted in increased numbers of nucleated cells,
granulocytes, CD34+ cells and haematopoietic progenitor cells in cord blood
(Lim FT et al., 2000). In their multivariate model where the explanatory variables
were the Apgar score, umbilical venous pH, durations of first and second stages
of labour and whether the labour was assisted or not, the explained variance (R2)
for cord blood nucleated cell, CD34+ cell an CFC content was 30%, 15% and
7%, respectively. Aufderhaar and collaborators have reported a positive
association between lower umbilical arterial pH, indicating a prolonged labour,
and higher cord blood nucleated, CD34+ cell and colony forming colony contents
(Aufderhaar U et al., 2003).
Mode of delivery. Cord blood nucleated cell concentration has been reported to
be higher in collections from vaginal deliveries compared with that in collections
from caesarean sections (mean 15.0 vs. 10.3 *109/l, respectively) (Vettenranta K
et al., 1997b). This is possibly due to cytokine interactions or oxidative sterss
elicited by various stress factors during vaginal delivery (Lim FT et al., 2000,
Aufderhaar U et al., 2003, Raijmakers MT et al., 2003). However, as the collected
volume is higher in collections from caesarean section deliveries than from vaginal
deliveries (76 vs. 63 ml, respectively) (Sparrow RL et al., 2002), the total nucleated
cell content obtained does not markedly depend on the mode of delivery.
In utero versus ex utero cord blood collection. Cord blood collection in utero
before the birth of the placenta has been reported to yield higher volumes than
collection ex utero after the birth of the placenta (mean 93 vs. 66 ml, respectively)
(Surbek DV et al., 2000c), and thus larger total nucleated cell, CD34+ cell and
colony forming cell numbers (Solves P et al., 2003b, Solves P et al., 2003a, Solves
P et al., 2003c). Wong and collaborators studied paired cord blood samples and
reported 9.5% higher concentration of nucleated cells and 11.6% higher
concentration of CFU-TOT colonies in samples collected in utero compared with
paired samples collected ex utero (Wong A et al., 2001). Discrepant data on the
microbial contamination rate in in utero and ex utero cord blood collections have
been reported (Lasky LC et al., 2002, Solves P et al., 2003a), probably due to
differences in obstetric practice or collection techniques. The procedures in cord
blood banking for unrelated transplantation are designed not to disturb the delivery
practices when the collections are performed ex utero.
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6 AIMS OF THE STUDY
The general aim of this study was to evaluate and develop methods for using the
vast amounts of data gathered in the cord blood banking process to analyse
various infant physiological phenomena and to improve the quality of the cord
blood haematopoietic stem cell transplant.
The specific aims were:
- to study the association between cord blood nucleated cell and CD34+ cell
content through the standardised banking process (I),
- to analyse the association between infant characteristics and human leukocyte
antigens in order to clarify the multiple factors affecting intrauterine growth (II),
- to study the association between infant characteristics and cord blood cell
concentrations in order to elucidate the effect of cord blood haematopoietic
progenitor and stem cell content to intrauterine growth (III), and
- to study the association between infant gender and cord blood cell
concentrations in order to reveal the independent effect of gender on cord blood
haematopoietic progenitor and stem cell content (IV).
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7 MATERIALS AND METHODS
The methods developed for the Finnish Cord Blood Bank programme were
reported in study I. The same methods were used to obtain the material for the
other studies (II-IV). The later studies included the material of the former. Although
the study materials thus overlapped, the accumulating number of infants included
in the studies during the developement of the banking programme improved the
reliability of the analyses. The Netcord/FAHCT standards (NETCORD and FAHCT,
2001) were applied wherever applicable in the cord blood banking programme.
7.1 Study subjects
7.1.1 Ethics
The procedures for the cord blood banking programme were accepted by the
Ethical Committees of the City of Helsinki and Vantaa (recruiting) and of the
Helsinki University Central Hospital (collections), and were carried out according
to the provisions of the Declaration of Helsinki. The mothers of cord blood donor
infants gave written informed consent for their participation in the cord blood
banking programme.
7.1.2 Material of the original studies
Cord blood collections for clinical use were began at the Department of Obstetrics
and Gynaecology, Helsinki University Central Hospital, in January 1999. From
January 1999 to October 2000 cord blood collections were performed at a single
collection hospital. After October 2000 cord blood was collected using identical
standards in two hospitals. One cord blood collection site was closed in November
2003. Altogether, 1999 cord blood collections were processed, frozen and
transferred to international search registries for clinical use as haematopoietic
stem cell transplants by September 2003 (Table 4).
Between January 1999 and October 2000, 3176 healthy pregnant women
registered voluntarily as prospective cord blood donors (I). Of these, 1067 (34%)
delivered in circumstances where the cord blood could be collected. The exclusion
of 313 (29%) of the 1067 collections from processing (Figure 3) was mainly due
to a low collected volume (N=284). Other reasons for discarding the collections
from processing were adverse maternal or infant health information (N=10) as
well as process development and validation and technical problems (N=19). Of
the 754 (71%) units accepted for processing, 93 were not processed further
because of a too low total nucleated cell number. Technical problems precluded
the further processing of 29 units. Of the 632 (59%) frozen units 33 (3%) were
thawed for process development and validation or because of technical problems
during freezing. Thus, 599 (56%) cord blood units were further evaluated. CD34+
cell results were not available from seven units and for four additional units
some other data were missing. A uniform set of data was available for 588 (55%)
cord blood units. CFU results were available for 88 (15%) cord blood units. 526
57
cord blood units were included in international search registries by the end of
May 2002. As typical in cord blood banking, only approximately half of the 1067
collections performed could be succesfully stored as clinical cord blood
transplants.
A complete set of HLA, CD34+ and nucleated cell data was available for 1381
cord blood collections performed between January 1999 and December 2001.
Of these, HLA DRB1 was investigated from 1263 samples (II) at a later phase of
the cord blood banking process. Apgar scores were seven or more in 98.4% of
the infants at one minute of age, and in all of them at 10 minutes of age. All
infants received normal care in the maternity unit. The birth weight of seven
(0.5%) infants was less than 2500 g. Forty-six infants (3.3%) were classified as
macrosomic (birth weight z-score >2SD).
In study III, 1368 term deliveries with gestational age 37 weeks or more were
analysed out of the total of 1381 cord blood collections. Of these collections,
1342 (98.1%) were from pregnancies between 37 and 42 weeks, and 26 (1.9%)
from pregnancies longer than 42 weeks. Fifty-four infants (3.9%) were classified
as macrosomic.
In study IV, 1999 cord blood collections further processed, frozen and
transferred to international search registries for clinical use as haematopoietic
stem cell transplants between January 1999 and September 2003 were analysed.
CFU results were available from 321 (16.1%) cord blood collections. The median
birth weight of the male infants (N=1059, 3715g, range [2425-5310]) was, as
expected, higher than that of female infants (N=940, 3570g, [2315-5410],
P<0.0001). There was no difference between male and female median relative
Table 4 Material of original publications.
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Table 5 Descriptive statistics of cord blood donors.
Figure 3 Study material: from
collections to cord blood units
accepted into the international
search registries (I). Reasons for
non-acceptance of cord blood
units for transfer to search
registries varied from medical
reasons to technical errors.
Aroviita et al. Vox Sanguinis
2003;84(3):219-27. Copyright of
Blackwell Publishing, used with
permission.
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birth weights (0.05, [-2.33–4.83] vs. 0.06, [-2.59–4.08], respectively, P=0.43). The
median gestational age of male infants (278d, [242-298]) did not differ from that
of female infants (277d, [255-298]), P=0.35).
Of the whole material of 1999 infants, 1948 (97.4%) were delivered at term
(37-41 weeks) and 940 (47%) were female. Forty-six percent of the deliveries
were caesarean sections. Indications for elective caesarean sections included
previous caesarean section, breech presentation and contractive pelvis. For
logistic reasons (timing of the birth, immediate delivery of the placenta, low
microbiological burden) caesarean section deliveries were preferred. The
distribution of birth weights was normal. Logically, the median relative birth weight
approached zero as the study material grew (Table 5). The median and distribution
of gestational ages were identical in all studies.
7.2 Cord blood banking (I)
7.2.1 Recruiting donor mothers
Pregnant women attending routine maternity health care visits were informed of
the possibility of donating cord blood and of the health requirements
(preselection). Mothers were also recruited during outpatient clinic visits. Healthy
volunteer mothers registered as prospective nonremunerated donors.
Baby health questionnaires, which were sent to well baby clinics, were used
to study the success of the preselection process performed by maternity health
care system and cord blood bank midwives in selecting cord blood units from
healthy mother baby pairs.
7.2.2 Collection
Mother’s written informed consent, health questionnaire and blood sample
Mother’s consent was obtained prior to the delivery either using a registration
form or in person by specially trained cord blood bank midwives. After delivery,
the mother confirmed her informed consent in written within seven days (usually
the day after delivery). The mother was also interviewed by cord blood bank
midwives regarding her and her family ’s health history using standard
questionnaires. The cord blood bank midwives drew the maternal blood samples
and obtained the obstetric and perinatal data from the hospital records.
Cord blood collection
Cord blood collections were performed ex utero at the Department of Obstetrics
and Gynaecology of the Helsinki University Central Hospital. The umbilical cord
was clamped and dissected according to the normal procedure of the hospital
delivery unit. After the placenta was delivered, it was wrapped in a sterile cloth
and transferred by a cord blood bank midwife to a specially equipped collection
room adjacent to the delivery rooms. The room was only used for cord blood
collections, which were performed by specially trained cord blood bank midwives.
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Equipment for collection
Placenta was placed in an autoclavable collection stand, which gives good support
to the placenta. After careful disinfection of the umbilical cord, umbilical vein
was cannulated and cord blood was collected into a cord blood collection bag
(791-01U, Pall Medsep Corporation, Covina, CA; 25 ml CPD anticoagulant) in a
closed system. The nominal volume of the collection bag was 150 ml, but in
practice a maximum of approximately 110 ml of cord blood could be collected
(see processing below). The collection time and the collected blood volume
were registered with weighing blood mixer (Optimix, Baxter, Kista, Sweden).
After collection, the tubing was stripped to mix all the blood with anticoagulant
and sealed (Hematron 3, Baxter Fenwall, Kista, Sweden).
Transportation of cord blood between collection hospital and processing
laboratory
Each collected cord blood was packed individually for transportation to the
laboratory; it was placed between thermoregulatory elements (butanediol bags)
in order to reach room temperature (17-26°C). Room temperature was chosen
for transportation instead of refrigeration to avoid unnecessary temperature
changes in the cord blood. The blood bag was then packed in an insulating
container together with a continuously registering electronic thermometer
(TinyTalk, Gemini Data Loggers, Dundee, Scotland; measurement every three
minutes) and a standard thermometer and transported to the laboratory by car.
On arrival at the laboratory the cord blood bag was placed on a platelet mixer
(Helmer, Baxter, Kista, Sweden) to await processing at room temperature.
7.2.3 Processing
Volume collected
Cord blood volume collected was defined as the total volume received in the
laboratory, excluding the volumes of the anticoagulant (25 ml) and the initial
sample (5 ml) (I). In studies II-IV the volume collected was defined as the total
volume received in the laboratory excluding only the volume of the anticoagulant
(25 ml). The total volume received in the laboratory was measured by weighing
the collection bag (AND EK-1200G, A&D Instruments, Oxford, UK) and reducing
the weight of the empty bag (18 g). One gram was taken as one millilitre.
Processing premises
Processing was performed in the Finnish Red Cross Blood Service (FRC BS)
Cord Blood Bank laboratory in special laminar air hoods. The positively pressurised
premises were used only for cord blood processing. Microbial cultures from
surfaces and air, as well as air particle measurements, were performed regularly
by the FRC BS microbiology laboratory and clean room contamination control
unit.
Acceptance criteria for processing
Cord blood collections with a collected volume of at least 50 ml with no adverse
maternal or infant health history or technical problems were accepted for
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processing. Units with volumes between 40 and 50 ml were processed if the
total collected nucleated cell count exceeded 800 x106 / unit. The cord blood
units were processed in 48 hours after collection.
Volume reduction and cryopreservation
The method described by Rubinstein and collaborators (Rubinstein P et al., 1995)
was applied for volume reduction. At each transfer step of cord blood, exact
calculations were performed to ensure a final volume of 20 ml. Briefly,
hydroxyethyl starch (HESPAN®, 6% colloidal solution of hetastarch in 0.9%
sodium chloride in water for injection, Fresenius Pharma, Graz, Austria) was
added to the collection bag in 1:5 ratio relative to the volume of cord blood
volume collected + anticoagulant. After the first centrifugation (46 g (400rpm),
18 min, 10°C, Sorvall RC3C, Kendro, Asheville, NC) the collection bag was attached
to the cord blood processing bag set (791-02U, Pall Medsep Corporation, Covina,
CA) using a sterile connecting device (SCD, Terumo, Leuven, Belgium), and
leukocyte rich plasma was extracted to the processing bag. After the second
centrifugation (400 g (1500 rpm), 13 min, 10°C, Sorvall RC3C) excess plasma
was removed using a manual extractor (Fenwall 4R4414, Fenwall Laboratories,
Deerfield, IL), and 5 ml mixture of cryoprotectant (55% w/v DMSO and 5% w/v
Dextran 40, Pall Medsep Corporation) was added on cooling plates in a
standardised way using an infusion pump (Ivac P600, Alaris Medical Systems,
Hampshire, UK). The final product was transferred to the freezing bag, which is
an integral part of the processing bag set. Segments were sealed to the freezing
bag tubing and 20 ml and 5 ml chambers were also sealed (Sebra 1105, Sebra,
Tuscon, AZ) to enable possible future separate use. The freezing bag was sealed
(Fuji FS-315, Fuji Impulse, Osaka, Japan) into a quarantine pouch (Overrap Bags
P/N 7-01-150, Thermogenesis, Rancho Cordova, CA) and placed in a metal canister
(P/N 6-16-146, Thermogenesis).
Controlled rate freezing and storage of cord blood units
The canister was then inserted in a Controlled Rate Freezer (P/N 7-65-009,
Thermogenesis) and the cord blood unit frozen using a specified freezing profile
(pre-freeze 10°C/min; start-freeze –1°C; fan power 100%; end-freeze –11°C; post-
freeze 2°C/min; end temperature –50°C) in a BioArchive system (Thermogenesis).
After freezing, the robotic arm automatically stored the unit in the liquid phase
of liquid nitrogen, where long-term storage takes place in a highly stable
environment. The median viability of the cell contents after thawing (Rubinstein
P et al., 1995) was 87% (N=8/33, range 72-98, Trypan-Blue method).
7.2.4 Laboratory analyses
The cord blood bank laboratory performed the CD34+ cell enumeration and
haematopoietic progenitor cell assays. All other laboratory tests were performed
in other laboratories of the FRC BS. The initial sample volume of 5 ml taken from
whole cord blood at the beginning of processing was used for nucleated cell
enumeration (0.5 ml), CD34+ cell enumeration (0.5 ml, from which also blood
smears for further morphology were archived), colony forming cell cultures (0.5
ml, from 15% of randomly selected cord blood units), HLA serological typing (3
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ml, from which the plasma fraction was archived for further tests) and
microbiological cultures (aerobic 0.5 ml, anaerobic 0.1 ml). Samples for nucleated
cell and CD34+ cell enumeration after volume reduction were drawn before the
addition of the cryoprotectant.
Standardised concentration
The ratio of standard anticoagulant volume used to actual cord blood volume
obtained in collection (without anticoagulant) varies. The result is a greater dilution
of smaller collection volumes leading to inappropriately lower measured
concentrations. This variable ratio was not corrected for in the cell concentration
data in study I. To study the associations between infant characteristics and
cord blood cell concentrations, the measured concentration was standardised
by dividing the total cell number collected by the cord blood volume collected
(excluding the anticoagulant). These actual values for CD34+ and nucleated cell
as well as for CFU concentrations were used in the analyses in studies III-IV as
well as in this thesis.
Archived samples
Samples of cord blood native plasma, HES plasma, excess red cells, umbilical
cord, DNA and blood smears, as well as maternal plasma and buffy coat were
stored for future studies (data not analysed in the present study).
Nucleated cell, erythrocyte and platelet enumeration
Cells counts were obtained using an automated haematology analyser (Sysmex
K1000, Sysmex Corporation, Kobe, Japan; method based on electric resistance
detection) at the FRC BS component production quality control department. The
nucleated red cell number was included in the total nucleated cell count.
Lymphocyte, monocyte and neutrophil concentrations were calculated by
multiplying the relative content of the respective cell type and the corrected
nucleated cell concentration (IV).
CD34+ cell enumeration
CD34+ cell analyses were performed using a flow cytometer (FacsCalibur; Becton-
Dickinson, San Jose, CA) and either a commercial single platform (ProCOUNT,
Becton-Dickinson, 1/1999-3/2001) or dual platform (ISHAGE, 3/2001-9/2003)
(Sutherland DR et al., 1996) protocol. The performance of the CD34+ cell analyses
was evaluated six times a year in an external quality control scheme with
successful results (UK NEQAS, National External Quality Assessment Service,
Sheffield, UK; adult CD34+ cells). Notably, the quality control samples were adult
mobilised peripheral blood.
Haematopoietic progenitor cell enumeration
Colony forming cells (colony forming units, CFU) were cultured as statistical
process control from 15% of randomly selected samples. 1x104 and 2x104
nucleated cells were plated in duplicate and cultured for 14 days in +37°C, 5%
CO2 without antibiotics using commercial reagents (Methocult GF H4434,
StemCell Technologies, Vancouver, Canada). Total CFU content (CFU-TOT) was
defined as the sum of granulocyte-macrophage (CFU-GM), burst-forming-unit-
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eryhrocyte (BFU-E) and multipotential granulocyte-erythrocyte-macrophage-
megakaryocyte (CFU-GEMM) colonies. Hemoglobinised colonies were analysed
as the sum of CFU-GEMM and BFU-E colonies. The performance of the analyses
was evaluated in an external quality control scheme biannually (Global Proficiency
Testing Program for Hematopoietic Clonogenic Assays (cell thawing, inoculation
and colony enumeration), StemCell Technologies, Meylan, France). The quality
control samples were adult mobilised peripheral blood.
Microbial cultures
Aerobic and anaerobic microbial cultures (BacTAlert™, Organon Teknika
Corporation, Durham, NC) were performed.
Infectious diseases testing
Blood donor infectious diseases screening tests (HIV1/2-antibodies, HCV-
antibodies, HBs-antigen, HTLV1/2-antibodies, cardiolipin-antibodies) were
performed on each maternal sample and cord blood collected as part of current
infectious diseases screening system at the FRC BS.
HLA typing (II)
HLA A and B antigens were typed serologically using commercial typing trays
(HLA ABC 144, Biotest AG, Dreieich, Germany). Low resolution DNA typing was
used to define DRB1 allele groups (Innolipa, Innogenetics, Murex Biotech Limited,
Kent, UK). DRB1*13 alleles were further typed using the DRB1*13 SSP high
resolution typing kit (Olerup SSP AB, Saltsjöbaden, Sweden).
7.2.5 Acceptance of cord blood units to search registries
After thorough evaluation of the obstetric and infant-related data, as well as the
data derived from the cord blood volume reduction process and laboratory
analyses, against standards (NETCORD and FAHCT, 2001) and predefined internal
criteria, acceptable cord blood units were included in international search
registries.
7.3 Statistics (I-IV)
Descriptive analysis was used in all studies. In study I, simple linear regression
(least squares equations) was used to analyse association between variables, all
of which followed either normal or truncated normal distribution.
A method of comparing extreme low and high centiles was used to test the
hypothesis of internal associations between infant characteristics and cord blood
cellular contents (II-III). Cord blood donor infants were sorted according to CD34+
cell concentration, nucleated cell concentration, relative birth weight and birth
weight, and opposite groups were formed from infants belonging to respective
opposite centiles (2.5th vs. 97.5th and 5.0th vs. 95.0th) (Figure 4). Non-parametric
Mann-Whitney U-testing was used for opposite group comparisons (for HLA
data analysis, see below).
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Binary decision tree was used to control possible confounding effects such
as delivery hospital, mode of delivery and CD34+ cell enumeration protocol (III,
IV). A multivariate linear regression model (best subset selection by examination
of all possible regressions) was built to explain the independent effect of studied
variables on cord blood CD34+ cell (III, IV) and CFU-TOT concentrations (IV).
Data were handled using Microsoft Excel® and Access® software. To ensure
coherent and reproducible data handling, Visual Basic for Applications
programming was used to create large data tables (II). Statistical anaylses were
performed using StatsDirect (StatsDirect Ltd, Sale, Cheshire, UK) software. Two-
sided P values <0.05 were considered to be statistically significant.
7.3.1 HLA data analysis (II)
The data were analysed in phases. First, a screening was performed where the
frequency of infants possessing an allele group in each of the opposite groups
(see above) was compared with the frequency in the Finnish adult population
(Siren MK et al., 1996). As the frequency of many HLA alleles in the general
population is low, only allele groups with frequencies >3% were considered for
screening. If the frequency of infants possessing the allele group in either of the
opposite groups exceeded, or, in order not to exclude possibly differing opposite
groups due to rounding errors, coincided with the 95% confidence limits of the
frequency in the Finnish adult population, the allele group was chosen for second
phase, where the allele group frequencies in opposite groups were compared
with each other using Fisher’s exact test. If differences were observed, a further
comparison against the expected frequency in an opposite group based on the
frequencies in all cord blood donor infants was performed.
To test whether the Hardy–Weinberg equilibrium applies to the distribution of
HLA phenotypes, an exact test using the Markov chain implemented in the
Arlequin program package (Schneider et al., 2000) was employed. The frequencies
of HLA A and B antigens were not compared between opposite groups, as the
absence of deviation from the expected Hardy-Weinberg distribution of the
phenotypes could not be shown (P<0.05). Instead, no deviation from the expected
Hardy-Weinberg distribution of the DR phenotypes could be shown (P=0.73).
HLA DRB1 allele group frequencies were defined by the counting method as
the percentage of cord blood donor infants carrying the allele group (Svejgaard
A and Ryder LP, 1994). No attempt was made to evaluate the possible dose–
response effect of HLA homotsygosity.
Eleven HLA DRB1 allele groups (Table 6) were initially screened for differences
in allele group frequencies in opposite groups. Seven DRB1 allele groups
(DRB1*13 found in comparisons of both relative birth weight and birth weight
groups) whose frequency in opposite groups deviated from the 95% confidence
interval of population frequency were selected for further comparisons using
Fisher’s exact test.
An improved Bonferroni procedure (Simes RJ, 1986, Armitage P et al., 2002)
was used to calculate the corrected error alfa levels for multiple HLA allele group
comparisons. P values were ordered so that P(1) < P(2) < … < P(n), and a
corrected error alfa level for each comparison was defined as alfacorr (x) = x * alfa
/ n, where x is the ordinal number of the P-value for the corresponding allele
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Figure 4 Opposite groups. Cord blood donor infants were ordered according to
selected parameters (CD34+ cell concentration, nucleated cell concentration (NC),
relative birth weight (Rel bw) and birth weight (Bw)); respective opposite groups
based on 2.5th vs. 97.5th as well as 5.0th vs. 95.0th centiles of each parameter were
formed for comparisons.
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Table 6b HLA B frequencies in cord blood donor infants (N=1381).
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group in the opposite group pair tested, alfa the original level of type alfa error
(0.05), and n the number of comparisons made. The number of HLA allele group
frequency pairs selected for further testing in screening was used to correct the
alfa error level for multiple comparisons in Fisher’s exact test.
7.3.2 Cord blood donor infants (II-IV)
Newborn infant data were obtained from hospital records. In addition to birth
weight, which was measured immediately after birth as part of normal neonatal
care, gestational age, mode of delivery and durations of the different stages of
vaginal delivery were recorded.
Relative birth weight
Relative birth weight was expressed as birth weight z-score using the z distribution
(Oken E et al., 2003) and a Finnish reference population (Pihkala J et al., 1989).
Macrosomia was defined as birth weight z-score >2 SD. No attempt was made
to exclude macrosomic infants from the study.
7.4 Contribution of the researcher
Pekka Aroviita has participated in applying all cord blood banking processes
including recruiting, collection, processing, testing, storing and release of
unrelated cord blood units. He has planned together with other collaborators the
design of all studies. Pekka Aroviita has analysed the data and was the first
author of all studies.
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8 RESULTS
8.1 Cord blood banking process (I)
8.1.1 Recruiting the donor mothers
Methods used by the cord blood banking program for selecting units from
healthy mother baby pairs
The success of the preselection process performed by cord blood bank midwives
in selecting cord blood units from healthy mother baby pairs was tested by
sending a health questionnaire to well baby clinics six months after the birth
between January 1999 and September 1999. Ninety-five % (172/181) of the baby
health questionnaires were returned in two months, and 166 infants were reported
healthy (Aroviita P et al., 2000 [abstract]). In three cases the reported diagnoses
were coarctation of the aorta, infantile spasm and facial paresis. In the three
other cases only symptoms and signs (vomiting, hearing defect, non-specific
symptoms) but no definite diagnoses were available from the well baby clinic.
The non-laboratory selection process was based on self-exclusion of the mother
prior to registration, on obstetric records before and after collection, and on
health questionnaires and interview of the mother. Only 3% of the babies were
not reported healthy six months from birth, which may be used as a quality
indicator of the selection process.
8.1.2 Collection of cord blood
Collection time
Cord blood bank midwives received the placenta immediately after its delivery.
The median collection time of 2min 17s (range 1min 10s – 6min 2s) of the cord
blood units frozen for further evaluation was uniformly short, as compared with
conventional blood banking.
Collected cord blood volume
The median cord blood volume collected for processing was 69 ml (range 28-
116, mean 72, SD 20). Five cord blood units were processed despite the blood
volume collected being less than 40 ml (28-37); these units were not accepted
for clinical use. The practice of measuring the nucleated cell content of the low
volume (40-50 ml) units before further processing proved that only 10% (10/103)
of these units contained a minimum target total nucleated cell number of 800
x106. The process was revised so that the nucleated cell content of all units was
measured before the decison for further processing.
Maintaining a uniform temperature profile of cord blood during transportation
between collection hospital and processing laboratory
To validate the cord blood transport procedure a sample of 107 shipments
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transported between November and August (median monthly temperatures in
Helsinki, Finland +1.4°C — -5.7°C — +16°C) was analysed in detail (Figure 5).
The median temperature of the shipments on arrival at the laboratory was
+19°C (range 17-22, mean 19, SD 0.9) (standard thermometer) and +19°C (range
17-23, mean 19, SD 1.1) (continuous monitoring). The minimum temperature
during transportation was never less than +17°C.
Effect of storage time on nucleated cell and haematopoietic progenitor cell
content of cord blood
The total nucleated cell number of collected cord blood or of cord blood units
before cryopreservation did not differ between the storage time groups of <8h
and 8-25h, and neither were the nucleated cell yields different (Aroviita P et al.,
2002 [abstract]). The median CFU-GM concentration of collected cord blood
was lower in the group stored between eight and 25 hours (N=68, 7/µl, range
[0.6-31]) than in the group stored less than eight hours (N=20, 11/µl [3-40],
P<0.04). There were no differences in median CFU-GEMM (<8h: 10/µl [0-24] vs.
8-25h: 12/µl [0.6-47], P=n.s.) or CFU-TOT (<8h: 19/µl [3-56] vs. 8-25h: 19/µl [2-
73], P=n.s.) concentrations between the storage time groups.
Figure 5 Temperature of cord blood during transportation between collection
hospital and processing laboratory (N=107, continuous temperature monitoring
every 3 minutes mean solid line, min/max broken lines). The median temperature
at the collection site was +24°C (range 23–26). The temperature after 3 min of
transportation was +23°C (range 18-26) and the profile reached the level of +18°C
- +19°C after one hour of transportation. Due to variation in the actual transport
times the number of observations is smaller in longer transportation time categories
(median transportation time 36 min (range 9-156)). Aroviita et al. Vox Sanguinis
2003;84(3):219-27. Copyright of Blackwell Publishing, used with permission.
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8.1.3 Cell yield and pre- versus post-processing correlations
Nucleated cells in cord blood units
The nucleated cell (NC) yield of the volume reduction process was 65% (range
34-83%, mean 64%, SD 7%). The two units (0.2%) in which the nucleated cell
yield was less than 40% were not accepted for search registries. The correlation
of the total nucleated cell numbers before and after volume reduction was strong
(equation: NCtotal_after = 0.61 x NCtotal_before + 2 x10
7, r=0.96, R2=0.92, P<0.0001),
suggesting a reliable and reproducible process.
CD34+ cells in cord blood units
The CD34+ cell yield of the volume reduction process was 74% (range 6-166%,
mean 75, SD 15). The correlation of the total CD34+ cell numbers before and
after volume reduction was clear (equation: CD34total_after = 0.70 x CD34total_before +
9 x104, r=0.96, R2=0.92, P<0.0001). There was also a correlation between the
CD34+ cell and nucleated cell concentration in cord blood collected (equation:
CD34conc_coll = 3.2 x NCconc_coll – 4.5, r=0.54, R
2=0.29, P<0.0001) and between the
total CD34+ cell and nucleated cell numbers in cord blood units before
cryopreservation (equation: CD34total_unit = 0.0038 x NCtotal_unit - 360000, r=0.64,
R2=0.41, P<0.0001).
Haematopoietic progenitor cells in cord blood units
The CFU results were available from 88 cord blood collections as a result of
random sampling (15% of cryopreserved units) for statistical process control. Of
these, 68 (15%) were from 447 units whose processing was started the next day
after collection (stored between eight and 25 hours before processing) and 20
(15%) from 130 units stored less than eight hours before processing. No CFU
results were available from any of the units stored between 25 and 48 hours
before processing (N=11). There were no differences regarding the volume
collected or the concentrations of nucleated cells, CD34+ cells or platelets in
this group (N=88) when compared with the whole material (N=588) (data not
shown).
The correlations between the total nucleated cell and CFU-TOT numbers and
between the total CD34+ cell and CFU-TOT numbers in collected cord blood
were good (equation: CFU-TOTtotal_coll = 0.0018 x NCtotal_coll –210000, r=0.69,
R2=0.47, P<0.0001 and equation: CFU-TOTtotal_coll = 0.57 x CD34total_coll + 220000,
r=0.87, R2=0.75, P<0.0001, respectively). Also, correlation between the total
CD34+ cell number in cord blood before cryopreservation and the total CFU-TOT
number in collected cord blood was strong (equation: CD34total_unit = 0,99 x CFU-
TOTtotal_coll + 220000, r=0.89, R
2=0.79, P<0.0001).
Erythrocytes in cord blood units
The removal of erythrocytes in the volume reduction process was 73% (range
34-89, mean 70, SD 11).
Platelets in cord blood units
The removal of platelets in the volume reduction process was 68% (range 34-80,
mean 68, SD 6).
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8.2 HLA and blood groups
8.2.1 Birth weight and HLA DRB1 (II)
HLA A and B antigen frequencies were not compared with published frequencies
in Finnish population (Siren MK et al., 1996), as the frequencies in the present
study deviated from the expected Hardy-Weinberg distribution.
The frequency of HLA DRB1*13 positive infants in the study material was
25.3% (95%CI 22.9-27.7) (Table 6). HLA DRB1*13 was found more frequently
among infants with the highest birth weights compared to those with the lowest
birth weights. The association was statistically significant when relative birth
weights were analysed (P=0.015) (Table 7), although it remained non-significant
after correction for multiple comparisons. The same trend was also observed
without correcting the birth weight for varying gestational ages (P=0.063). Over-
expression of DRB1*13 in infants of higher relative birth weight was evident also
in the 90.0th vs. 10.0th and 97.5th vs. 2.5th centile opposite groups (data not shown).
The HLA DRB1*13 allele (*1301-03) frequencies in the opposite groups formed
by relative birth weight did not differ.
Table 7 Comparison of the frequency of selected HLA allele groups between opposite
groups formed by infant as well as cord blood characteristics.
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Figure 6 Infants in the highest 5.0% centile of relative birth weight had statistically
significantly higher CD34+ cell concentrations than infants in the lowest 5% centile
(N=66 in both). Extreme values were removed (N=2 in both). Aroviita et al. Acta
paediatrica 2004;93(10):1323-9. Copyright of Taylor & Francis, used with
permission.
When the birth weights (or relative birth weights) of all infants positive (N=319)
or negative (N=944) for the DRB1*13 were compared, the association was
evident: the median birth weight (or relative birth weight) of HLA DRB1*13 positive
infants was higher than that of HLA DRB1*13 negative infants (3690g vs 3650g,
P=0.044; 0.186 vs 0.083, P=0.025; respectively).
The frequency of HLA DRB1*08 positive infants in the study material was
16.3% (95%CI 14.3-18.3). HLA DRB1*08 was found more frequently than
expected among infants with the lowest birth weights (P=0.034, non-significant
after correction for multiple comparisons). However, the difference between the
median birth weights of HLA DRB1*08 positive (N=206) and negative (N=1057)
infants was not statistically significant (median 3630 g vs 3670 g, P=0.566).
Table 8 Association between blood groups and cord blood cell concentration
(N=1999).
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8.2.2 Blood groups (unpublished results)
The frequencies of the ABO and Rh blood groups were similar in 2490 cord
blood collections (data not shown), in 1999 cord blood units accepted for clinical
use (Table 8) and in Blood Service’s entire collection of blood donors (Nevanlinna
HR, 1972). In the 1999 cord blood units accepted for clinical use, no differences
in nucleated cell or CD34+ cell concentrations between A, B, AB and O, Rh(D)
positive versus negative or Kell positive versus negative blood groups were
observed (Table 8).
8.3 Cord blood transplant (I, III, IV)
8.3.1 Associations between infant and cord blood characteristics
Birth weight (III)
Nucleated cells. The correlation between birth weight and cord blood nucleated
cell concentration was statistically clearly significant, although the R squared
was low. This indicates that other factors also influence the cell concentration.
Cord blood nucleated cell concentration did not correlate with relative birth weight
or with placental weight.
CD34+ cells. The correlation between birth weight and cord blood CD34+ cell
concentration was statistically clearly significant. Again, low R squared indicates
that other factors also influence the concentration. The correlations between
relative birth weight and cord blood CD34+ cell concentration and between
placental weight and CD34+ cell concentration were similarly statistically
significant with low R2 values.
Infants with the highest birth weight or with highest relative birth weight (95.0th
centile) had roughly double the concentration of cord blood CD34+ cells as
compared to those of infants in the lowest birth weight groups (5.0th centile)
(median 38 vs 22/µl, and 45 vs 20/µl, respectively, P<0.0001 in both). Correcting
the opposite groups for extreme CD34+ cell concentrations by removing the
lowest and highest values (N=68 —> N=66) did not diminish the level of
statistical significance (Figure 6).
In multivariate linear regression analysis using a sample from one collection
hospital where all CD34+ cell analyses were performed using the ProCOUNT
protocol (N=694), the correlation between birth weight and CD34+ cell
concentration was statistically highly significant after adjusting for the number
of deliveries, length of gestation, mode of delivery, sex, and nucleated cell
concentration (III) (Table 9).
Gender (IV)
Nucleated cell concentrations. The median cord blood nucleated cell
concentration of female infants was higher than that of male infants (13.9 vs.
13.3 *109/l, respectively, P=0.0001). This difference was mainly due to the higher
neutrophil concentration of female infants compared to that of male infants, as
illustrated in the cumulative frequency graphs (Figure 7). The nucleated cell
concentration in infants delivered vaginally was higher than that in infants
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delivered by caesarean section. This difference consisted equally of all nucleated
cell subgroup concentrations. Female infants from both caesarean section and
vaginal deliveries had higher nucleated cell concentrations than the respective
male infants, the difference in both modes of delivery consisting of the higher
neutrophil concentration of female infants.
CD34+ cell concentrations. The median cord blood CD34+ cell concentration of
all male infants (N=1059, 31.8/µl, range [1.9-208]) was higher than that of female
infants (N=940, 30.2/µl [5.4-237], P=0.03). Although the difference in absolute
numbers appears small, it was 5.3%. The difference was statistically significant
also in a sample from one collection hospital with all CD34+ cell analyses
performed with the ProCOUNT protocol (Figure 8).
Haematopoietic progenitor cell concentrations. The cord blood CFU results were
available from N=321 of N=1999 infants (16%). The median CFU-TOT
concentration of male infants (N=154, 21.9/µl, range [3.4-136]) tended to be
higher than that of the female infants (N=167, 19.8/µl [0.5-94], P=0.10).
Interestingly, the male infants had higher median CFU-GEMM concentration than
female infants (11.1/µl [0.0-47] vs. 9.9/µl [0.0-53], respectively, P=0.03), while
there was no difference in median CFU-GM concentrations (9.1/µl [1.4-56] vs.
8.0/µl [0.6-53], respectively, P=0.23).
Multivariate linear regression analysis.The difference in cord blood haematopoietic
progenitor cell concentrations between male and female infants was also
analysed using multivariate linear regression in a sample from one collection
hospital where all CD34+ cell analyses were performed using the ProCOUNT
protocol (N=637). In this model the male gender was associated statistically
Figure 7 Cumulative frequency of cord blood nucleated cell concentrations of
male (N=1059) and female (N=940) infants. Any given point in these graphs
represents the percentage of infants (y axis) that have at least the respective cell
concentration (x axis).
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significantly with higher CD34+ cell concentration after adjusting for the mode
of delivery and the relative birth weight (IV) (Table 9).
Gestational age (III)
Gestational age of term infants did not correlate with cord blood CD34+ cell
concentration (Figure 9), in contrast to the positive correlation with the nucleated
cell concentration. This explains the previously reported negative correlation
between the percentage of CD34+ cells of nucleated cells and gestational age
which was also apparent in this study.
Mode of delivery (I, III-IV)
Volume and nucleated cell content of cord blood (I). The median cord blood
volumes collected from vaginal deliveries (N=326) and caesarean sections
(N=262) were 61 ml (range 28-116, mean 66, SD 18) and 80 ml (range 42-114,
mean 80, SD 19), respectively (P<0.0001). There were no differences in the total
collected nucleated cell numbers in vaginal and caesarean section delivery groups
(96.3 x107 (range 34.7-250, mean 104, SD 40) and 92.8 x107 (range 35.4-320,
mean 102, SD 42), respectively, P=n.s.), as the nucleated cell concentrations of
cord blood collected from vaginal and caesarean section deliveries differed in
the opposite direction compared with the collection volumes (11.1 x109/l (range
5.1-22, mean 11.5, SD 3.2) and 9.1 x109/l (range 4.4-29, mean 9.7, SD 3.0),
respectively (P<0.0001)).
Figure 8 Cumulative frequency of CD34+ cell concentrations of male (N=336)
and female (N=301) infants. All collections were from one collection hospital
and the CD34+ cell analyses were performed using the ProCOUNT protocol. Male:
median 35.1 /µl, range [7.2-177], mean 42.3, SD 26; Female: 32.9 /µl, [5.6-128],
38.5, 24, Mann-Whitney U-test P=0.04.
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Figure 9 Correlations between gestational age and cord blood cell concentrations.
CD34+ cell concentration: r=-0.002, P=0.95; nucleated cell concentration: r=0.35,
P<0.0001; CD34+ cells / nucleated cells: r=-0.23, P<0.0001. Cord blood
collections were from one collection hospital and CD34+ cell analyses were
performed with ProCOUNT protocol (N=694). Aroviita et al. Acta paediatrica
2004;93(10):1323-9. Copyright of Taylor & Francis, used with permission.
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Figure 11 Cumulative frequency of cord blood CFU-Mixed colony concentrations
in caesarean section (N=134) and vaginal (N=187) deliveries.
CD34+ cell concentration (IV). In the whole material of 1999 infants, there was
no difference between the median CD34+ cell concentrations from caesarean
section (N=916, median 30.8 /µl, range [1.9-181], mean 36.7, SD 24) and vaginal
deliveries (N=1083, median 31.8 /µl, [4.1-237], 38.5, 27, P=0.24).
Birth weight and CFU-TOT concentration (III). Vaginal and caesarean section
deliveries were analysed separately to discover whether possible associations
Figure 10 Correlations between birth weight and CFU-TOT concentration in vaginal
(N=63) and caesarean section deliveries (N=51). Vaginal delivery: r=0.05, P=0.70;
Caesarean section: r=0.52, P=0.0001. Modified from Aroviita et al. Acta
paediatrica 2004;93(10):1323-9.
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between birth weight and cord blood CFU-TOT concentrations might vary
according to mode of delivery. An association between birth weight and CFU-
TOT concentration of cord blood was clear in infants delivered by caesarean
section, while in infants delivered vaginally a statistically significant association
was not observed (Figure 10).
Differences in the cumulative distributions of the CFU concentration according
to mode of delivery and gender (IV). The cumulative frequency distributions of
the CFU concentrations of caesarean section deliveries were clearly different
from those of vaginal deliveries, the difference being most apparent in CFU-
Mixed (equivalent to CFU-GEMM) concentrations (Figure 11), although no
differences in CFU-TOT and CFU subgroup concentrations according to the
delivery mode were detected in Mann-Whitney U-testing (P=0.55-0.98). The
distribution of the CFU-Mixed concentrations of cord blood collected from
caesarean section deliveries was more uniform than the distribution of the CFU-
Mixed concentrations of cord blood collected from vaginal deliveries (25th-75th
percentiles in caesarean section and vaginal deliveries: 6.4-14.4 vs. 5.4-17.0 /µl,
respectively).
When caesarean section and vaginal deliveries were analysed separately, the
difference between CFU concentrations of male and female infants was again
most apparent in CFU-Mixed concentrations. The CFU-Mixed concentrations of
male infants were statistically significantly higher than those of female infants
in caesarean section deliveries (median 12.0/µl, range [0.8-26] vs. 10.0/µl [0.0-
34], respectively, P=0.01) compared with CFU-Mixed concentrations in vaginal
deliveries (11.0/µl [0.0-47] vs. 9.8/µl [0.0-53], respectively, P=0.45) (Figure 12).
Collected cord blood volume (unpublished results)
Collected volume and birth weight. Collected cord blood volume (N=1999) had
Figure 12 Cumulative frequency of cord blood CFU-Mixed colony concentrations
of male (N=61) and female (N=73) infants in caesarean section deliveries and of
male (N=93) and female (N=94) infants in vaginal deliveries. Modified from
Aroviita et al. Transfusion 2005;45 (In Press).
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a statistically significant correlation with birth weight (r=0.27, 95%CI for r =
0.232 - 0.313, R2=0.07, P<0.0001). The correlation was also clear between
collected volume and relative birth weight (r=0.32, 95%CI for r = 0.277 - 0.356,
R2=0.10, P<0.0001). Correlation between collected cord blood volume and
placental weight (r=0.39, 95%CI for r = 0.353 - 0.427, R2=0.15, P<0.0001) was
statistically significantly higher than the correlation between collected volume
and birth weight based on comparison of the 95% confidence intervals for r.
Placental weight had the strongest correlation (P<0.0001) with the collected
cord blood volume also in a multivariate linear regression analysis after adjusting
for the birth weight (P=0.23), relative birth weight (P=0.98), number of births
(P=0.51) and gestational age (P<0.0001).
Collected volume and cell concentration. Correlations of collected cord blood
volume (N=1999) with nucleated cell (r=-0.14, 95%CI for r = -0.18 - -0.10,
R2=0.02, P<0.0001) as well as with CD34+ cell concentration (r=0.10, 95%CI
for r = 0.06 – 0.15, R2= 0.01, P<0.0001) were weak. No correlation of collected
cord blood volume (N=321) with CFU concentration was observed (r=0.07, 95%CI
for r = -0.04 – 0.17, R2=0.00, P=0.24).
8.3.2 Haematopoietic cell content (I, III, IV)
Collected cord blood volumes as well as cord blood CD34+ and nucleated cell
concentrations of study III (N=1368) were comparable to those reported in studies
I (N=588) and IV (N=1999). Cell contents in collected cord blood and in cord
blood units after volume reduction (i.e. before cryopreservation) are presented
in Table 10, Figure 13 and Figure 14.
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Table 10 Cell content of cord blood collections and units (partly unpublished
results).
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Table 10 (cont.)
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Figure 13 Histogram of the nucleated cell concentrations of collected cord blood
(N=1999, median 13.6 *109/l, range 6.0-38.1).
Table 10 (cont.)
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Figure 14 Histogram of the CD34+ cell concentrations of collected cord blood
(N=1999, median 31.2 /µl, range 1.9-237).
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9 DISCUSSION
Accepted methods of blood transfusion service practice, in addition to specific
international cord blood bank standards, were adopted in the Finnish Cord Blood
Bank programme, the methodology and results of which are described and
discussed in studies I-IV. The Finnish Cord Blood Bank with all its activities
(collection, processing, testing, banking, selection and release) was awarded
accreditation by the FACT (Foundation for the Accreditation of Cellular Therapy)
in September 2004. In the present study, infant and obstetric characteristics
were collected prospectively in a uniform computerised system to allow analysis
of selected internal relationships. Cord blood cell contents from a large uniform
material of 1999 cord blood donors and cord blood units for transplantation
were analysed.
A standard amount of anticoagulant is routinely used in cord blood collection,
whereas the collected cord blood volume varies. This causes the blood/
anticoagulant ratio in collection bags to vary, smaller blood volumes being diluted
more than larger ones. Cord blood banks naturally calculate the total number of
cells of a collection using the measured concentration data. However, the
measured values in the cord blood banking process cannot be used as such to
estimate the actual cord blood cell concentration. If the anticoagulant is deducted
from the total volume and the measured concentration is corrected for this native
blood volume, the corrected, or standardised, concentrations may be used to
estimate the effects of gestation, labour and selected infant characteristics on
the cell counts in cord blood. These standardised concentrations were used in
studies III-IV as well as in this thesis.
In this study series, haemoglobin (Hb), haematocrit (Hkr), mean corpuscular
volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular
haemoglobin concentration (MCHC) and mean platelet volume (MPV) were not
analysed. Erythrocyte and platelet yields were analysed in the volume reduction
process (I). Thawing and potential washing of the cryopreserved cord blood unit
before transplantation is normally the responsibility of the transplant centre.
However, thawing validation data are available from the cord blood bank.
9.1 Nucleated cell content of cord blood transplants
Nucleated cell content has been used in graft selection to predict the
haematopoietic potential of a cord blood transplant (Lim F et al., 1999). Rubinstein
and collaborators have reported faster myeloid engraftment in cord blood
transplant recipients who were infused the highest nucleated cell numbers per
kilogram of body weight (Rubinstein P et al., 1998). Estimations of nucleated cell
dose needed for successful cord blood transplantation vary (Gluckman E et al.,
1997, Gluckman E, 2000). Gluckman has suggested a dose limit of >2*107 cord
blood nucleated cells per kilogram of patient body weight at the time of collection
(Gluckman E, 2001). On the basis of this suggestion, 18% and 47% of the single
units stored in the Finnish Cord Blood Bank by September 2003 would have
been adequate for patients weighing 70kg and 50kg, respectively. A consistent
cell dose threshold has not been set, although the significance of higher cell
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dose for successful cord blood transplantation has been well documented
(Gluckman E et al., 2004). According to recent reports, cord blood units actually
used for transplantation have contained high cell numbers, e.g. a median
nucleated cell number of 142*107 (Oudshoorn M, Foeken-van Goozen L, 2004).
Even if neutrophil engraftment has been rapid with a large total nucleated cell
dose, this dose has had less influence on the speed of platelet engraftment.
White blood cell concentration of healthy newborn infants has a wide normal
variation (mean+SD 7.71+4.99 *109/l) (Forestier F et al., 1991). In our studies,
too, a wide variation in nucleated cell concentrations in cord blood samples of
term infants was observed (median 10.2 *109/l, range [4.4-26.6], Table 8), which
is also in accord with normal reference values in haematological textbooks (Nathan
DG et al., 2003).
Cord blood nucleated red blood cell concentrations between 0.3 and 1.1 *109/
l have been reported (Thilaganathan B et al., 1994a, Stevens CE et al., 2002). The
nucleated cell concentration obtained from fresh cord blood samples with
haematology analyser used in this study (Sysmex K1000) includes nucleated red
cells. However, including nucleated red blood cells in the total nucleated cell
count has been shown not to hamper the reliability of using the total nucleated
cell content as an estimate of the haematopoietic potential of a cord blood
transplant (Stevens CE et al., 2002).
A proportion of newborn infants may have very high white blood cell
concentrations (>30-40 *109/l). Supposing a maximum cord blood nucleated
cell concentration of 40 *109/l and a collected volume of 250 ml, 1000 *107
nucleated cells could theoretically be collected. As the factors related to delivery
and infant health underlying these high cell concentrations cannot be fully
explored, it is not necessarily wise to aim for high cell concentration alone in the
quest for high haematopoietic progenitor and stem cell contents. The extent to
which high cell concentrations should be pursued remains to be determined on
the basis of future cord blood transplantation results.
Good collaboration between the delivery room and cord blood collection staff
is invaluable. In order to avoid clots in the cord blood unit, the collection should
start as soon as possible after clamping of the cord and should last only two to
three minutes, at most five minutes. Factors inherent in the cord blood banking
process may affect the obtained cord blood volume; e.g the size of the collection
bag may limit the maximum collected cord blood volume. To obtain cord blood
collections with high cell content, several cord blood banks have adopted a
selection process that captures only the highest collected cord blood volumes
for banking. As the collected volume does not predict the nucleated cell
concentration, the cell concentration of each collection is currently analysed
before the decision to process further or not. However, this implies collecting a
number of small cord blood units which will not end up in long-term storage.
Collected cord blood volume can also be increased by modifying the collection
techniques, e.g. using flushing of the umbilical vein (Elchalal U et al., 2000).
These methods are more labour intensive and prone to microbial contamination
and activation of coagulation, and may not be suitable for clinical cord blood
banking. Collecting cord blood in utero before the birth of the placenta has been
reported to yield higher volumes (Solves P et al., 2003b). This, however, may
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imply interfering with the delivery process.
Several obstetric factors possibly affecting the cord blood cell content, e.g.
gestational age, birth order, mode of delivery and length of the stages of vaginal
labor have been studied (Donaldson C et al., 1999, Ballen KK et al., 2001, Jones
J et al., 2003), among many others. In the present study, nucleated cell
concentration of term infants was shown to correlate positively with gestational
age of term infants (III). As birth weight, relative birth weight and placental weight
correlated positively with the collected cord blood volume, higher expected birth
weight, together with higher gestational age, could be used for predicting high
volume cord blood collections, and cord blood collections could consequently
be directed to deliveries of largest infants. Otherwise, the studied obstetric factors,
although they can be assessed pre-delivery, have only marginal predictive value
for the cord blood cell yield, and thus selecting infants for cord blood donation
based on these factors is not generally feasible.
Adequate results in clinical transplantation have been obtained using the
nucleated cell content to evaluate the haematopoietic potential of cord blood.
Although the correlation between nucleated cell and colony forming cell
concentration in cord blood is clear (r=0.58) (I), the nucleated cell content may
not reflect optimally the full haematopoietic progenitor and stem cell content of
a given unit. Thus, improved markers for predicting the haematopoietic potential
of a cord blood transplant would be needed.
9.2 CD34+ cells
The single platform ProCOUNT protocol was developed in an international effort
to enumerate CD34+ cells accurately and to diminish inter-laboratory variation
(McNiece I et al., 1998, Dzik W et al., 1999). The ProCOUNT protocol was used to
analyse CD34+ cells in the beginning of present study according to the instructions
of the manufacturer. When ProCOUNT reagents became unavailable on the
market, the dual platform ISHAGE protocol (Sutherland DR et al., 1996) to
enumerate CD34+ cells was adopted from March 2001 in the Finnish Cord Blood
Bank. The differences in the results obtained with two different methods were
taken into account in the analyses (I, III, IV).
Compared to the present study, similar median CD34+ cell total numbers in
collected cord blood have been reported (2.2-2.3 *106/unit, range 0.007-28.0)
(Armitage S et al., 1999b, Ballen KK et al., 2001). CD34+ cell concentrations have
been documented less often. Surbek and collaborators reported a median CD34+
cell concentration of 34 /µl (range 7-121) in preterm deliveries of 33-36 weeks
gestational age (Surbek DV et al., 2000b), which accords with the median
concentration of 24.9 /µl (range 2.3-180) in term infants of the present study (I).
Despite interlaboratory differences, the described results reflect similar levels of
CD34+ cells in cord blood.
Parallel total CD34+ cell numbers in ex utero collections both after vaginal
(2.96+2.25 *106/unit) and caesarean section delivery (3.08+1.97 *106/unit) have
been reported (Solves P et al., 2003c). Likewise, in the present study, the
concentrations between the median CD34+ cell concentration in vaginal (33.2 /
µl) and caesarean section deliveries (34.1 /µl, P=0.81) did not differ (IV).
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In our studies, the correlation between pre- and post-volume-reduction cord
blood CD34+ cell concentrations was shown to be extremely good, suggesting a
uniform and reliable process of enriching collected cord blood CD34+ cells into
the final transplant (I). CD34+ cell concentrations, both pre- and post-volume-
reduction, were also shown to correlate well with the CFU colony concentration
in collected cord blood, the correlation being clearly better than that between
nucleated cells and CFU colonies. Similar results, the  correlation between cord
blood CD34+ cell and colony forming cell concentration (r=0.62) being better
than between cord blood nucleated cell and colony forming cell concentration
(r=0.50), have also been reported earlier (Lim F et al., 1999). Thus, as CFU colony
content of a cord blood transplant has been reported to be a good predictor of
its haematopoietic potential (Migliaccio AR et al., 2000), a high concentration of
CD34+ cells may be considered a marker of rapid haematopoietic progenitor and
stem cell production, or production in high numbers.
CD34+ cell content of a cord blood transplant has also been studied as a
predictor of the haematopoietic potential in clinical setting (Wagner JE et al.,
2002). However, lack of international cord blood CD34+ cell standard has prevented
the standardisation of CD34+ cell enumeration methods (Barnett D et al., 1998).
Therefore, widespred use of CD34+ cell content as a criterion for selecting cord
blood collections for clinical transplants can not be promoted. Still, cord blood
CD34+ cell content can be used in internal evaluation and comparisons of the
haematopoietic potential of transplants in an individual bank.
9.3 CFU
Only few studies have reported cord blood colony forming unit concentrations.
The median CFU-TOT concentration in the present study, 22.4 /µl (range 4.3-136)
(Table 10), compares favourably with the median haematopoietic progenitor cell
concentration of 15.4 /µl (range 0.7-87.0) reported by Lim and collaborators (Lim
F et al., 1999).
Colony forming cells are reported in cord blood in approximately similar
concentrations as CD34+ cells, suggesting that both methodologies cover at
least partially overlapping haematopoietic cell types. The correlation between
CFU and CD34+ cell concentration in the present study was good (r=0.81) (I).
However, as the cells are allowed to grow for two weeks, CFU cultures cannot
be used in selecting cord blood collections for cord blood banking process.
Although standardisation of CFU culture methodology is still not adequate (Clarke
E et al., 2002 [abstract]), cord blood banks may use CFU cultures in internal
comparisons.
Correlations between nucleated cell, CD34+ cell and colony forming cell content
of cord blood have been demonstrated. However, until more specific methods
to enumerate stem cells are developed, best estimation of the haematopoietic
potential of a given graft is obtained with laying more emphasis on the
simultaneous analysis of all existing information on the haematopoietic potential
of a single cord blood unit.
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9.4 Birth weight
Normal birth weight varies widely depending both on gender and gestational
age, and thus a specific measure to account for both of these factors is needed.
Thus, relative birth weight, or birth weight z-score, which represents birth weight
corrected for gestational age and gender, is used in obstetrics. Birth weight z-
scores from a sample are interpreted as if they arose from a normally distributed
population (Pihkala J et al., 1989, Oken E et al., 2003).
Positive correlations of birth weight with collected cord blood volume and
thus with higher total cell counts have been reported (Ballen KK et al., 2001,
Jones J et al., 2003). However, in these reports separating the individual effect
of cord blood cell content from the volume of collected cord blood was not
reported. We put forward the hypothesis (III) that a high concentration of
haematopoietic progenitor and stem cells would reflect intrauterine growth, and
on this basis we analysed the relationship of cord blood cell concentrations
(CD34+ cells, nucleated cells, and colony forming cells) with birth weight in term
pregnancies.
CD34+ cell concentration was almost double in infants belonging to the 95.0th
centile of relative birth weight compared with those belonging to the 5.0th centile
(III). Also, the infants in the top 50.0th centile (above median) of relative birth
weight had higher median CD34+ cell concentration than infants in the low 50.0th
centile (below median) in a subgroup, where all CD34+ analyses were performed
using a single platform protocol. The positive correlation between birth weight
and CD34+ cell concentration remained statistically clearly significant even after
adjusting for other variables in multivariate regression analysis. Ballen and
collaborators have reported a positive correlation between birth weight and total
CD34+ cell content of cord blood in their study of 1240 collections (Ballen KK et
al., 2001). To our knowledge, a positive correlation between cord blood CD34+
cell concentration - not confounded by collected blood volume - and birth weight
has not been reported earlier.
Cord blood progenitor and stem cells may have a more central role in
intrauterine growth and development than has been reported earlier. Higher
observed haematopoietic progenitor cell concentration may also reflect
differences in other progenitor and stem cell lineages. Interestingly, multi-potent
mesenchymal cells have been isolated also from cord blood (Lee OK et al., 2004,
Lee MW et al., 2004).
9.5 Gender
As gender was not used to select cord blood collections for processing, 47% of
cord blood donors were female in this study. Geographically, cord blood was
collected from donors resident in the capital area, which is considered well
representative of the general Finnish population.
In study III, we demonstrated an association between higher cord blood CD34+
cell concentration and higher infant birth weight. We thus formed the hypothesis
that cord blood haematopoietic progenitor and stem cell concentration, measured
as CD34+ and colony forming colonies, would not only associate with birth weight
but also with infant gender.
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Indeed, male infants were observed to have higher cord blood CD34+ cells
concentration than females (IV). The difference between male and female median
CD34+ cell concentrations was, although small, still statistically significant (5.3%,
P=0.03). In a recent report, where 572 samples from cord blood bank collections
were analysed, the difference of 11% between male and female median CD34+
cell concentrations (30 vs. 27 /µl, respectively) did not reach statistical significance
(P=0.36) (Nakagawa R et al., 2004).
Our findings were confirmed using multivariate linear regression analysis,
where male gender was associated with higher CD34+ cell concentration (P<0.05)
after adjusting for mode of delivery and relative birth weight. Thus, gender may
affect the characteristics of cord blood haematopoietic progenitor cell transplants.
Although cord blood from male infants was observed to have 5% higher CD34+
cell concentration than that from female infants, the difference does not justify
collections from male donors only. Despite intensive research, the complex
mechanisms underlying gender differences, including multiple genetic factors
in addition to sex hormones, are only beginning to unravel (Dennis C, 2004).
9.6 Effect of the mode of delivery
CFU-Mixed concentration distributions of male and female infants differed in
caesarean section deliveries compared with those in vaginal deliveries, although
the total CFU concentrations according to the mode of delivery did not differ. In
caesarean section deliveries, male infants had significantly higher CFU-Mixed
concentrations than female infants, while in vaginal deliveries difference in CFU-
Mixed concentrations between male and female infants was not statistically
significant (IV). This dissimilarity observed in the present study between CFU-
Mixed concentrations of male and female infants in caesarean section deliveries
compared with those in vaginal deliveries could not be explained by any technical
factor in the study setting. Notably, when CFU-Mixed concentrations from all
caesarean section and all vaginal deliveries were compared, a central tendency
in the concentrations from caesarean section deliveries was observed. While
the range of cord blood CFU-Mixed concentrations was comparable between
cesarean section and vaginal deliveries, in the latter the 25th-75th percentile
concentration range was wider. This probably reflects activating factors during
labor, which might cause either a stimulating or depressing effect on the regulation
of progenitor cells. Accordingly, associations of various stress factors during
labor with cord blood CFU content has been demonstrated (Lim FT et al., 2000,
Aufderhaar U et al., 2003).
Study III also revealed a correlation between CFU-TOT concentration and birth
weight in caesarean section deliveries but not in vaginal deliveries. Thus, cord
blood collections from caesarean section deliveries may represent better sampling
from the in vivo situation, and may facilitate evaluations of physiologic phenomena
during gestation. The possible effect of the delivery mode on transplant outcome
remains to be studied.
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9.7 HLA and blood groups
HLA population data derived from clinically oriented studies often remain small
due to the expenses involved in HLA typing. Valuable HLA distribution data have
been derived from volunteer bone marrow donor registries (Siren MK et al., 1996,
Schipper RF et al., 1997, Mori M et al., 1997, Brown J et al., 2000), revealing
considerable ethnic variance.
Cord blood donors represent a population of healthy infants. As cord blood
donors are HLA typed the data of the most common HLA types may be used for
analysing the association of HLA with infant physiological phenomena. In the
present study, comparisons of HLA allele frequencies between the bone marrow
donor registry and the cord blood bank were not possible because of the changing
typing accuracy of serological and molecular techniques over time.
In study II we were able to explore associations between cord blood bank and
HLA DRB1 data because DRB1 typing was performed by a DNA method. To our
knowledge this possibility has not been utilised earlier. Although the number of
infants in the study (N=1263) was large, the low prevalence of many alleles of
the polymorphic loci of the HLA system rendered all but preliminary analyses
impossible.
HLA DRB1*13 was shown to be over-represented in infants with the highest
birth weights, suggesting a possible growth advantage for HLA molecules or
some unknown factor linked to the HLA DRB1 region of chromosome 6 in normal
intrauterine growth and development (II). As DRB1*13 has been associated with
protection from infectious diseases (Hill AV et al., 1991, Apple RJ et al., 1994,
Thursz MR et al., 1995), the mechanism could be through molecular host
responses. An association like this presents challenges for further research on
the molecular level.
Recently, longer thrombocytopenia periods have been documented after major
ABO-incompatible peripheral blood progenitor cell transplantation (Canals C et
al., 2004). Data on the possible association between HLA match and slower
platelet engraftment in transplantations using cord blood as compared with cells
from adult sources is scarce. Thus, it is not possible to exclude the potential
effect of HLA matching on the speed of platelet engraftment after cord blood
transplantation.
In the present study, no association between nucleated or CD34+ cell
concentrations and ABO, Rh or Kell blood group frequencies were observed. To
our knowledge, this has not been reported earlier. At the time of the study, the
frequencies of ABO and Rh blood groups in the Finnish Cord Blood Bank were
similar to those in the healthy adult Finnish population. In the future, as infants
are being selected for cord blood collection to increase cell yields, cord blood
bank data will not represent normal distributions of tissue types, blood groups
and haematopoietic progenitor and stem cell concentrations in healthy infants.
9.8 Unrelated cord blood as a haematopoietic transplant
Lack of accurately HLA-matched haematopoietic stem cell donors has justified
the search of alternative stem cell sources. Transplantation of unrelated bone
marrow or peripheral blood stem cells has become an established alternative
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(Thomas ED et al., 1975a, Davies SM et al., 2000). Cord blood has proven a
promising option in children, and lately also in adult patients.
Even though the required HLA match may be more relaxed for a cord blood
transplant than for a transplant from adult sources, better matching may also improve
cord blood transplantation results (Rubinstein P et al., 1998). One HLA mismatch
has been suggested to be equivalent to a dose of 3*107 cord blood nucleated cells
per kilogram of patient weight (Rubinstein P et al., 2000 [abstract]). Transplantation
results using HLA matched (6/6) cord blood units are still scarce, however.
Increasing the infused cord blood nucleated cell dose in general has also
been reported to yield improved outcomes. Thresholds of 2-4 *107 nucleated
cells per kilogram of patient weight have been suggested for cord blood
transplantation (Gluckman E, 2000, Gluckman E, 2001). Cord blood has been
succesfully transplanted to adult patients provided that the cell dose has been
adequate (see above) or a double transplantation has been given (Barker JN et
al., 2005).
Cord blood is collected after normal pregnancy and delivery from a healthy
term infant with no known associated risk factors for disease. Cord blood
collection poses no risk to the donor as it is always performed after clamping of
the cord. Moreover, cord blood carries a low risk of transmitting infectious
diseases (Rubinstein P et al., 1993). Collections from both vaginal and caesarean
section deliveries have proven successful, yielding high collected blood volumes
with predictable pre- and intra-delivery obstetric and infant-related factors, such
as gender, affecting the cord blood quality.
As shown in this study, a well-standardised cord blood banking process may
yield tranplants with highly predictable haematopoietic progenitor and stem cell
contents. However, as cord blood banks currently select units with highest cell
counts for cryopreservation, the possible contents of the present-day transplants
may not be in line with the reported ones and may thus warrant further studies.
The volume reduction method (Rubinstein P et al., 1995) adapted in use during
this study has been shown to produce clinically effective transplants . Also, as
the processing methods are developed further, the real benefit of change must
be validated to result in at least as good clinical outcome as the classical
processing method.
Time required for cord blood unit acquisition can be kept short for patients in
urgent need of transplantation (Dalle JH et al., 2004). Once identified through an
international bank search, a cord blood unit is made available after confirmation
of its identity through repeat HLA typing of a bag segment, and preferably also
its viability with colony forming culture (Goodwin HS et al., 2003). The unit is
then transferred to the transplant centre before the patient’s conditioning
treatment begins, thus leading to reduced time from diagnosis to transplant. A
wide variety of archived samples is available in case of further requested analyses.
Long term outcome after cord blood transplantation has been comparable
with bone marrow transplantation although engraftment after cord blood
transplantation is delayed. Recently, comparable long-term outcome results of
unrelated cord blood transplantation and allogeneic-related haematopoietic stem
cell transplantation have even been reported (Jacobsohn DA et al., 2004).
Cord blood transplants do not contain ABO isoagglutinins. Cord blood has
also been reported to yield low incidence of severe acute GVHD (Rocha V et al.,
95
2001). Evidence is growing that cord blood transplants carry a GVL effect similar
to that of haematopoietic stem cell transplants from adult sources (Jacobsohn
DA et al., 2004).
Poor or delayed immune reconstitution is a common problem after
haematopoietic progenitor and stem cell transplantation. Cord blood contains
primitive haematopoietic progenitor and stem cells with proliferation potential
at least comparable to adult bone marrow or peripheral blood cells (Haneline LS
et al., 1996, Carow CE et al., 1991, Theilgaard-Monch K et al., 1999, Pettengell R
et al., 1994). Although haematopoietic engraftment and immune reconstitution
after cord blood tranplantation may be slower than after transplantation of a
graft from an adult donor, the long-term regenerative potential of both
immunologic and haematopoietic systems may be in favour of cord blood
transplantation (Talvensaari K et al., 2002, Frassoni F et al., 2003).
The size and number of active cord blood banks are growing steadily, reflecting
the encouraging results from clinical studies. Currently, up to 200 000 cord blood
units is estimated to be in storage in public cord blood banks and, although
exact statistics are not available, between 5000 and 6000 cord blood
tranplantations have been performed worldwide (Sanz MA, 2004, Steinbrook R,
2004). Future studies will reveal whether development of spesific cell components
(e.g. NK cells, cytotoxic T-lymphocytes) from cord blood is possible for clinical
use (Ayello J et al., 2004 [abstract], Satwani P et al., 2004 [abstract]). Current
information technology provides the means to explore the possibilities of
transforming the vast amounts of data gathered in a cord blood banking process
into valuable information for further development of cord blood transplants.
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10 CONCLUSIONS
The validation of policies and procedures adopted in a cord blood bank were
described in the present study. Cord blood bank data were prospectively collected
in a spreadsheet application specifically developed for the purpose. After
hypotheses were created, the data were explored using a variety of statistical
approaches, including descriptive analysis, comparison of groups based on
extreme high and low centiles of selected parameters, as well as multivariate
linear regression analysis.
Highly significant internal associations of cord blood cell concentrations, which
are considered to reflect the haematopoietic progenitor cell content, between
collected cord blood and processed cord blood units were observed. These
associations proved that the applied volume reduction process was predictable,
and that the laboratory tests themselves produced highly repeatable results over
a time period of four years. In addition, the excellent correlation observed between
whole blood CFU concentration and cord blood unit CD34+ cell concentration
suggests that the CD34+ cell determination can be used for evaluating the
haematopoietic potential of cord blood transplants within a single laboratory.
Volume of a cord blood collection has traditionally been the main determinant
of whether the collection was selected for processing or not. Several obstetric
and infant related variables were analysed to help clarify those affecting the
cord blood cell concentrations. Birth weight, especially relative birth weight, of
term infants was shown to be the single most important variable predicting
higher nucleated and CD34+ cell concentrations. Thus, the results indicate that
collection of cord blood from high birth weight infants with higher cell
concentrations yields the highest total cell contents in the cord blood transplant.
Also, cord blood from male infants was shown to have higher CD34+ cell
concentration and, in caesarean section deliveries, more abundant early series
haematopoietic progenitors than cord blood from female infants. These new
findings may suggest further gender-dependent differences in other progenitor
and stem cell lineages.
A significant and previously unreported association between HLA DRB1*13
and higher relative birth weight could be derived from the molecular DRB1 typing
routinely tested in all cord blood transplants prior to their release to international
search registries. This association may be of particular importance, as previously
described DRB1*13 associations have demonstrated protective characteristics
against infectious diseases.
The evidence accumulated shows that important new predictive factors
affecting cord blood transplant quality, as well as useful information about
neonatal physiology, can be derived from cord blood bank data originating from
a well-standardised process. As cord blood banks place more and more emphasis
on selecting for long-term storage only those collections with highest cell
contents, future data collections may no longer reflect physiological variation.
However, what is urgently needed is the development of more specific means
for evaluating each cord blood unit for its stem cell content and plasticity.
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